

AMR Action UK

England & Wales · Charity number 1157884

Details

Other names	ANTIBIOTIC RESEARCH UK - DEVELOPING NEW ANTIBIOTICS, ARUK
Status	Registered
Legal form	CIO
Registered	2014-07-16
Register	View on the Charity Commission register

Contact

Address	167-169 Great Portland street 5th Floor London W1W 5PF
Phone	02046 385 361
Email	info@amr-action-uk.org
Website	https://amr-action-uk.org/

Activities

Objects: TO PROTECT AND PROMOTE THE HEALTH OF THE PUBLIC, IN PARTICULAR BY SPONSORING RESEARCH INTO THE DIAGNOSIS, TREATMENT AND CURE OF ANTIBIOTIC-RESISTANT BACTERIAL INFECTIOUS DISEASES, ENSURING RESPONSIBLE AND SUSTAINABLE DEVELOPMENT AND DEPLOYMENT OF THE FINDINGS OF SUCH RESEARCH, AND RAISING AWARENESS THROUGH PUBLIC-FACING ACTIVITIES AND THE PROMOTION OF NETWORKS TO SHARE EXPERIENCE OF SUCH MATTERS.

Activities: AMR Action UK is the leading UK patient charity for Antimicrobial Resistance (AMR). We support those affected by AMR, and advocate for the changes that can happen right now - in all four nations of the UK - to protect people and families.

Classification

- **How:** Makes Grants To Organisations, Provides Other Finance, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** Children/young People, Elderly/old People, People With Disabilities, The General Public/mankind

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£406,889	£470,817	-	-
2023-12-31	£477,064	£464,809	-	-
2022-12-31	£399,824	£399,574	-	-
2021-12-31	£409,696	£446,521	-	-
2020-12-31	£445,648	£353,667	-	-

Trustees

Name	Role	Appointed
Rosemary Howell	Chair	2022-10-20
Christine Richardson		2024-02-21
Clare Kerr		2024-02-21
Ghada Zoubiane		2024-02-21
Peter Kirkpatrick		2024-02-21
Rose Gray		2024-02-21

Accounts

Charity registration number 1157884 (England and Wales)

AMR ACTION UK
FORMERLY ANTIBOTIC RESEARCH UK - DEVELOPING NEW
ANTIBIOTICS
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

AMR ACTION UK

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Ms Rosemary Howell	
	Ms Ghada Zoubiane	(Appointed 21 February 2024)
	Dr Christine Richardson	(Appointed 21 February 2024)
	Dr Peter Kirkpartrick	(Appointed 21 February 2024)
	Ms Clare Kerr	(Appointed 21 February 2024)
	Ms Rose Gray*	(Appointed 21 February 2024)
	Ms Fiona Russell*	(Resigned 13 August 2024)
	Mr Phil Robinson*	(Resigned 31 May 2024)

*Also, member/observer of the Finance Committee

Chief Executive Officer	Jonathan Pearce	(Resigned 26 July 2024)
	Kirsteen Wills	(Appointed 19 August 2024)

Science and Patient Support Committee	Dr Mike Allen	
	Dr Tina Joshi	
	Professor Chris Schofield (ex-official since January 2024)	
	Dr Joe Standing (2nd Term of Office ends 30th March 2025)	
	Dr Mark Sutton (2nd Term of Office ended 30th November 2024)	
	Dr Oliver Van Hecke	
	James Amos (2nd Term of Office with PEPS committee ended August 2024 & moved to SPEC Committee March 2024)	
	Dr Alison Staples	
	Dr Neil Todd	

Charity number (England and Wales)	1157884
---	---------

Principal address	167-169 Great Portland Street
	5th Floor
	London
	W1W 5PF

Independent examiner	Tom Wilcox
	Counterculture Partnership LLP
	23 St Leonards Road
	Bexhill-on-Sea
	East Sussex
	TN40 1HH

AMR ACTION UK

CONTENTS

	Page
Trustees' report	1 - 6
Independent examiner's report	7
Statement of financial activities	8
Balance sheet	9
Notes to the financial statements	10 - 19

AMR ACTION UK

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees present their annual report and financial statements for the year ended 31 December 2024.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Charities Act 2011, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)".

Objectives and activities

Who we are and what we do

AMR Action UK (formerly Antibiotic Research UK) is a national organisation, founded in 2014. It is the Patient Organisation (PO) for Antimicrobial Resistance (AMR) in the UK. The charity works to prevent the harm from the impacts of antimicrobial resistance to people in the four nations of the United Kingdom and campaigns for policy changes and for changes in healthcare practice which benefit patients and families. The charity's work is informed by our patient and public engagement, our direct support of patients through our services and through our patient-centred research activities.

About antibiotic and antimicrobial resistance

Antibiotic resistance, that is when infectious bacteria become resistant to antibiotic treatment, is on the rise globally. Antimicrobial resistance (AMR) is a broader term that includes bacteria, viruses, fungi and parasites that develop resistance to antimicrobial medicines. An article published in *The Lancet* in 2022 estimated that, in 2019, 1.27 million people died globally directly from an antibiotic resistant infection (Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al, "Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis", *The Lancet*, 2022; 399 (10325):629-5), a figure higher than people dying from HIV or malaria. This figure is alarming and whilst the highest number of deaths were in lower- and middle-income countries, COVID has shown us how quickly an infectious agent can spread around the globe.

According to the Institute for Health Metrics and Evaluation (IHME), in 2019 there were 7,600 deaths attributable to antimicrobial resistance (AMR) and 35,200 deaths associated with AMR in the UK (see "The burden of AMR in the UK" by IHME, University of Washington, University of Oxford and Global Research on Antimicrobial Resistance; available from <https://www.healthdata.org/antimicrobial-resistance/policy-briefings>). The IHME report also points out that the number of UK deaths from AMR is "higher than deaths from digestive diseases, diabetes and kidney diseases, other non-communicable diseases, unintentional injuries, and self-harm and interpersonal violence".

Purpose

The charity's purposes are set out in its constitution, as follows:

"... to protect and promote the health of the public, in particular by sponsoring research into the diagnosis, treatment and cure of antibiotic-resistant bacterial infectious diseases, ensuring responsible and sustainable development and deployment of the findings of such research, and raising awareness through public-facing activities and the promotion of networks to share experience of such matters."

Public benefit

The organisation's work delivers public benefit by funding and developing research to address the issue of antibiotic and antimicrobial resistance.

The organisation also provides invaluable support and assistance to those directly affected by antimicrobial resistance, as well as to the healthcare practitioners working with them. Reliable, evidence-based information and peer support helps patients and families to navigate their conditions and improve their longer-term health outcomes.

The charity provides wider benefit to the public through its work to influence policymakers, and to change practices within healthcare systems, including the NHS.

The charity regularly reviews how its activities have benefited those groups of people we are set up to help, referring to the Charity Commission's guidance on public benefit.

AMR ACTION UK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Achievements and performance

Antibiotic resistance, and AMR more widely, remains a major global health issue, on a par with climate change, but receiving far less attention nationally and internationally. In May 2024 the National AMR Action Plan was published, detailing actions that will be taken across the four nations of the United Kingdom – England, Scotland, Wales and Northern Ireland – to prevent the growth of AMR and those affected by it and to improve treatment.

In early 2024, the charity decided to focus strongly on one of the key areas of patient concern that came to us via our patient support service – chronic and recurring urinary tract infections. UTIs are one of the world's most common infections, yet the condition is neglected in terms of research into treatments and diagnostics. Anyone can get a UTI, and at any age, but older women are more prone. As the figures below illustrate, the number of cases in the UK and worldwide is alarming and the global burden of UTIs is rising: between 1990 and 2019 the rate of deaths from UTIs grew 2.4 times.

Up to 50% of women will suffer from an acute UTI at some point in their life, with 20-30% of women who have had a UTI being subject to a recurrence. In the UK, UTIs are the second most common healthcare associated infection (an infection acquired from a healthcare setting such as a hospital), accounting for 17.2% of all such infections. UTIs are also a major driver of antibiotic prescribing in primary care, with multidrug resistant infections rising. In addition, UTIs are one of the most common causes of sepsis as diagnosed/treated in hospitals, which can be fatal.

While often regarded as a mild 'bladder complaint', the numbers of patients experiencing recurrent and chronic/complex UTIs, due to the infection becoming resistant to antibiotic treatment, is growing. The impact of a drug-resistant UTI upon a patient can be life changing. Those who contact our charity for support tell us of ongoing pain, misdiagnosis, and the impact that drug-resistant infections have on their lives.

In March 2024 the charity convened a conference of patients, clinicians and policy-makers.

The **'Living with Chronic and Complex UTIs.'** conference (on 21st March 2024), attended by over 250 delegates (in person and online), facilitated engagement with patients, healthcare professionals (HCPs) and researchers. Feedback was very positive, for example: *"Insightful, thought provoking, hopeful."* and *"Extraordinary. Cutting edge science together with compassion and respectful inclusion of patients."*

In the summer of 2024, working in partnership with James Lind Alliance and with two other charities, we launched the Priority Setting Partnership for chronic and recurrent UTIs. This is a ground-breaking piece of work because when it reports in early 2026, it will be the collective view of patients and medical professionals as to the research that is currently missing in this important area and how these research areas should be prioritised. This information will be available to universities and other researchers to inform their future research programmes. The preliminary results of this work will be announced at a follow-up conference for 18th September 2025 *'Advances in Chronic and Recurrent UTIs'*.

Outside of UTI, the charity continued to fund research projects which once again illustrate the charity's role in early-stage research that address patient concerns. For example, The Neonatal Antimicrobial Resistance and Outcome (neoAMRO) study set out to understand the infections and risk factors contributing to neonatal deaths across UK neonatal units. By conducting a case-control study, the team assessed whether inappropriate antibiotic management, such as incorrect choice, dosage, or timing was linked to poor outcomes. The study aimed to identify infections responsible for neonatal deaths, characterise the affected babies, and examine antimicrobial treatments and resistance. Ultimately, the findings are intended to inform clinical guidance and improve care practices to reduce mortality among newborns. The neoAMRO study found that most neonatal deaths from infection were caused by resistant Gram-negative bacteria, especially *E. coli* and *Serratia marcescens* and highlighted the need for better guidelines to improve antibiotic selection and treatment in newborns.

Within Patient Services, individuals living with resistant infections and their families continued to receive personalised support and information from our Patient Support Team, via phone, email, plus on-line peer support sessions to help them to access treatment and support as well as to live with the chronic impacts of AMR-related conditions. Over 300 patients were helped in 2024.

AMR ACTION UK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Fundraising

The current fundraising environment continues to be challenging for the charity with donations affected by high inflation, the cost-of-living crisis and national economic challenges. We were pleased to continue to receive support via two vital multi-year grants, the first from the Oak Foundation to support capacity-building within the charity, and the second from the National Lottery Fund, supporting the continuation of our Patient Support Services. As always, we are enormously grateful to those who donated and volunteered on our behalf. Without their support we would not be able to continue our vital work.

Fundraising highlights in 2024 included:

- £50,000 from the Garfield Weston Foundation - £25,000 for 2025 and £25,000 for 2026.
- A further £38,000 secured to fund our research programme from a number of Trusts and Foundations.
- £97,218 from a range of corporate sponsorship and grants, including:
 - £39,598 from GSK in support of our project "Antibiotic Resistance: Video Case Studies for Storytelling", and a further £10,000 from GSK via our Corporate Supporter Circles Programme.
 - £19,799 from MSD, who supported our Video Case Studies project alongside GSK.
 - £14,071 from Pfizer Limited who provided us with funding to host our follow-up conference in September 2025, making a similar contribution to A. Menarini Farmaceutica Internazionale SRL who provided funding towards the end of 2023.
 - £5,000 from each of Advanz Pharma and Shionogi as contributors to the Circles Programme.

Financial review

The consolidated gross income for the year was £406,889 (2023: £477,065). The consolidated net movement in funds for the year was a loss of £63,928 (2023: surplus of £12,252).

Reserves policy

The trustees aim to maintain a minimum of free reserves equal to 3 months' core expenditure (approximately £69,800). Any funds over this sum are used to fund the charity's objects. The year-end level of free reserves was £124,202 (2023: £56,445). While this is a welcome improvement, to achieve long-term sustainability the charity has identified a need to grow unrestricted reserves, including building a more predictable and reliable funding base.

AMR ACTION UK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Risk assessment and management

The charity regularly reviews risks relating to its operations. The main areas of identified risk identified are:

- Regulatory and compliance risks, especially in relation to the burden of compliance within a very small organisation.
- IT security, which could impact business continuity.
- Operational risks due to the organisation's reliance on a small number of key individuals.
- Financial risks, especially in relation to levels of unrestricted reserves.

To address these risks measures have been put in place as follows:

- Ensuring Trustees, committee members and staff have solid experience and expertise in their fields, including in relation to regulatory requirements.
- The outsourcing of ICT support to ensure continuous monitoring and management of IT systems.
- A move away from short-term contractor arrangements towards permanent staff roles.
- Strong financial oversight from the Finance Committee and Board of Trustees.
- Maintaining third-party liability and indemnity insurance.

Plans for future periods

Following the appointment of the new CEO in August 2024, a review of the charity's strategy was undertaken, with this work completing in early 2025.

When Antibiotic Research UK was founded 11 years ago, it was positioned within a context of discussions that focused on "antibiotic resistance". The environment within which the charity is operating has changed in the intervening period. Discussions are no longer about "antibiotic resistance" alone, but "antimicrobial resistance" within a "one health" approach. With growing understanding, antimicrobial resistance has become shortened over the years to "AMR" which is now standard terminology in all of the spheres in which the charity operates, for example, with policymakers and within NHS systems.

Since 2019, the range of activities the charity is involved in has also expanded beyond its original research focus. For example, the charity provides a much-valued helpline for patients and families impacted by AMR, and it has become a leading advocate for AMR patient voice – ensuring the voices of patients are heard in the right places.

The Trustees of the charity, and its senior management team, believed that to better reflect and represent the charity's mission and its activities in its current-day context, a name that aligns more closely with the AMR policy and research contexts, and with our patient support and our patient voice activities, would more accurately articulate our mission to a wider range of stakeholders, increase opportunities for influence with policy-makers and NHS systems, and widen our funding base.

Following an EGM on 2nd May 2025 the name of the charity was changed to AMR Action UK.

With the organisation having continued to be heavily dependent on grants and trusts through 2024, and with two multi-year grants coming due to come to an end in 2026, in order to create longer-term financial sustainability, the further expansion of corporate fundraising and a much higher proportion of income coming from public fundraising and philanthropy have been identified as key priorities for late 2025/2026.

AMR ACTION UK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Structure, governance and management

Constitution and Trustee recruitment and appointment

Antibiotic Research UK was registered as a charitable incorporated organisation (CIO) on 16th July 2014. Antibiotic Research UK also previously had a wholly owned trading subsidiary, ANTRUK Enterprises Ltd, which was registered at Companies House (company registration no 10396024). The trading company was wound-up in 2024.

At an EGM on 2nd May 2025, by a unanimous vote, a name change for the charity was approved by members. It is now called AMR Action UK. This change of name was to reflect the much wider range of work which the charity now undertakes.

The work, management, finances and strategy of the charity are overseen by a Board of Trustees. The Trustees who held office during the financial year and at the date of the report are set out on page 1. The constitution requires there to be a minimum of three Trustees and a maximum of twelve Trustees in office at any one time. Trustees that are appointed at an annual general meeting (AGM) retire from office after a full term of three years, at the following AGM. However, Trustees that are appointed directly by the Board of Trustees in between AGMs must step down at the next AGM, but can stand for re-election at that AGM, and if so re-elected, their first three-year term of office starts at that point. A Trustee can seek re-election for a further three-year term of office but not a third term without an interval of a year.

The trustees who served during the year and up to the date of signature of the financial statements were:

Mr Simon Dukes* (Chair)	(Resigned 30 June 2025)
Ms Fiona Russell	(Resigned 13 August 2024)
Ms Rosemary Howell	
Ms Ghada Zoubiane	(Appointed 21 February 2024)
Dr Christine Richardson	(Appointed 21 February 2024)
Dr Peter Kirkpartrick	(Appointed 21 February 2024)
Ms Clare Kerr	(Appointed 21 February 2024)
Ms Rose Gray*	(Appointed 21 February 2024)
Mr Phil Robinson*	(Resigned 31 May 2024)

Recruitment and appointment of trustees

An annual review of the recruitment needs of the Board of Trustees is carried out under the leadership of the Chair, including an audit of the current knowledge, experience, skills and abilities, and how the Board will be affected by any planned trustee departures in the future. Any Trustee vacancies are advertised nationally, and via relevant professional and organisational networks, including the charity's own supporter base, depending upon the expertise and specialisms required. Applicants are shortlisted against the criteria in the person specification for the role of Trustee, including any specific qualities highlighted during the above audit. Shortlisted applicants are invited for interview by at least two Trustees, one of whom will be the chair. Shortlisted applicants are only appointed where they have the necessary skills and qualities to contribute effectively to the charity's governance and development. All new Trustees receive thorough induction and training, which includes information about the organisation's constitution, accounts, financial reports and minutes of previous Trustees' meetings.

Since year-end 2024, Simon Dukes has retired as Chair and the charity is undertaking an open recruitment process to appoint a new Chair. We are grateful to Simon for his support of the Charity through times of considerable change. The charity has also agreed to seek the appointment of a Treasurer, who will additionally Chair our Finance Committee. Further recommendations from the new CEO are to follow in late 2025.

Management and organisation

Day-to-day operation of the charity, and strategy implementation, is delegated to the Chief Executive Officer, who works for the charity on a part-time basis. The CEO is supported by a small management team, also employed on a part-time basis, plus suitably qualified and experienced team members in the areas of patient and family support, and Patient and Public Engagement (PPI). The charity also has a small fundraising team focused on creating a sustainable income stream so that the charity can both continue with, and grow, its vital work.

In July 2024 the Chief Executive Officer, Jonathan Pearce, stepped down from the role and in August 2024 Kirsteen Wills was appointed CEO.

AMR ACTION UK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Board of Trustees

The Board of Trustees meets at least four times a year to review the organisation's work, finances and services, and to agree the strategic goals for the charity. The Chief Executive Officer attends all meetings.

A Finance Committee comprising at least three Trustees meets quarterly to monitor and scrutinise the charity's financial performance, including its approach to management of funds, treasury and reserves. Recommendations from this committee are presented to the full Board of Trustees.

The Board also operated an advisory committee during 2024 called the Science, Education and Policy Committee. This committee had oversight of, and could give specialist advice in respect of, the charity's research programme. It could also advise on technical aspects of educational materials and policy positions. This committee comprises a mix of trustees and specialist advisors.

The trustees' report was approved by the Board of Trustees.

Rosemary Howell
.....

Ms Rosemary Howell
Interim Chair

Date: 13th October 2025
.....

AMR ACTION UK

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF AMR ACTION UK

I report to the trustees on my examination of the financial statements of AMR Action UK (the charity) for the year ended 31 December 2024.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011.

I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011. In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the Charities Act 2011.

Independent examiner's statement


Since the charity's gross income exceeded £250,000, the independent examiner must be a member of a body listed in section 145 of the Charities Act 2011. I confirm that I am qualified to undertake the examination because I am a member of Fellow Member of the Association of Charity Independent Examiners, which is one of the listed bodies.

Your attention is drawn to the fact that the charity has prepared the financial statements in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn. I understand that this has been done in order for the financial statements to provide a true and fair view in accordance with UK Generally Accepted Accounting Practice.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the Charities Act 2011.
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of financial statements set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the financial statements give a true and fair view, which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Tom Wilcox

Counterculture Partnership LLP

23 St Leonards Road

Bexhill-on-Sea

East Sussex

TN40 1HH

Date: 15/10/2025

AMR ACTION UK

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2024

		Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
	Notes						
Income from:							
Donations and legacies	3	41,762	-	41,762	41,856	42	41,898
Charitable activities	4	218,210	118,716	336,926	205,843	208,297	414,140
Other trading activities	5	22,638	5,563	28,201	21,027	-	21,027
Total income		282,610	124,279	406,889	268,726	208,339	477,065
Expenditure on:							
Raising funds	6	97,662	1,630	99,292	115,522	-	115,522
Charitable activities	7	181,701	189,824	371,525	126,996	222,295	349,291
Total expenditure		279,363	191,454	470,817	242,518	222,295	464,813
Net income/(expenditure)		3,247	(67,175)	(63,928)	26,208	(13,956)	12,252
Transfers between funds		64,510	(64,510)	-	-	-	-
Net movement in funds	9	67,757	(131,685)	(63,928)	26,208	(13,956)	12,252
Reconciliation of funds:							
Fund balances at 1 January 2024		56,445	396,886	453,331	30,237	410,842	441,079
Fund balances at 31 December 2024		124,202	265,201	389,403	56,445	396,886	453,331

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

AMR ACTION UK

BALANCE SHEET

AS AT 31 DECEMBER 2024

	Notes	2024 £	£	2023 £	£
Current assets					
Debtors	13	14,276		7,955	
Cash at bank and in hand		543,853		614,855	
		<u>558,129</u>		<u>622,810</u>	
Creditors: amounts falling due within one year	14	(168,726)		(169,479)	
Net current assets			389,403		453,331
			<u><u>389,403</u></u>		<u><u>453,331</u></u>
The funds of the charity					
Restricted income funds	16	265,201		396,886	
Unrestricted funds	17	124,202		56,445	
		<u>389,403</u>		<u>453,331</u>	
			<u><u>389,403</u></u>		<u><u>453,331</u></u>

The financial statements were approved by the trustees on 8th October 2025

Rosemary Howell
Ms Rosemary Howell
Interim Chair

AMR ACTION UK

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

Charity information

AMR Action UK is a Charitable Incorporated Organisation in England.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's Memorandum of Association, the Charities Act 2011, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)". The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a statement of cash flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

AMR ACTION UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

AMR ACTION UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

(Continued)

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Income from donations and legacies

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Donations and gifts	41,762	-	41,762	41,856	42	41,898
Donations and gifts						
Donations	10,000	-	10,000	13,115	-	13,115
Gift Aid	6,044	-	6,044	5,556	-	5,556
Online giving	23,438	-	23,438	23,185	42	23,227
Tribute	2,280	-	2,280	-	-	-
	41,762	-	41,762	41,856	42	41,898

4 Income from charitable activities

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Charitable activities						
Trust and foundations	186,210	45,248	231,458	104,528	208,297	312,825
Corporate income	32,000	73,468	105,468	101,315	-	101,315
	218,210	118,716	336,926	205,843	208,297	414,140

AMR ACTION UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

5 Income from other trading activities

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Membership fees	3,342	-	3,342	3,480	-	3,480
Fundraising events	10,527	-	10,527	15,133	-	15,133
Other	8,769	5,563	14,332	2,414	-	2,414
	<u>22,638</u>	<u>5,563</u>	<u>28,201</u>	<u>21,027</u>	<u>-</u>	<u>21,027</u>

6 Expenditure on raising funds

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Fundraising and publicity						
Fundraising expenses	3,578	-	3,578	11,012	-	11,012
Fundraiser fees	94,084	1,630	95,714	104,510	-	104,510
	<u>97,662</u>	<u>1,630</u>	<u>99,292</u>	<u>115,522</u>	<u>-</u>	<u>115,522</u>

AMR ACTION UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

7 Expenditure on charitable activities

	Total 2024 £	Total 2023 £
Direct costs		
Direct Project Grant	65,693	165,907
Other Direct Project Costs	37,221	18,120
Computer & software	7,766	7,635
Consultancy costs	112,113	84,277
Insurance	743	945
Printing, Postage & stationery	808	626
Website & IT	34,516	7,648
Phone & Internet	602	240
Travel & Subsistence	6,158	2,132
Bank charges	653	818
Recruitment Costs	3,750	1,535
Annual lecture	34,966	-
Sundry Costs	83	26
Other Legal & Professional Fees	49,158	47,369
Other charitable expenditure	-	1,600
	<u>354,230</u>	<u>338,878</u>
Share of support and governance costs (see note 8)		
Governance	17,295	10,413
	<u>371,525</u>	<u>349,291</u>
Analysis by fund		
Unrestricted funds	181,701	126,996
Restricted funds	189,824	222,295
	<u>371,525</u>	<u>349,291</u>

8 Support costs allocated to activities

	2024 £	2023 £
Governance costs	17,295	10,413
Analysed between:		
Total	<u>17,295</u>	<u>10,413</u>

AMR ACTION UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

9	Net movement in funds		2024	2023
			£	£
	The net movement in funds is stated after charging/(crediting):			
	Fees payable for the independent examination of the charity's financial statements		2,760	2,910
10	Trustees			
	None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.			
11	Employees			
	The average monthly number of employees during the year was:			
			2024	2023
			Number	Number
	Total		-	-
	There were no employees whose annual remuneration was more than £60,000.			
12	Taxation			
	The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.			
13	Debtors		2024	2023
			£	£
	Amounts falling due within one year:			
	Trade debtors		5,001	1
	Amount owed by parent undertaking		-	328
	Other debtors		-	88
	Prepayments and accrued income		9,275	7,538
			14,276	7,955
14	Creditors: amounts falling due within one year		2024	2023
			£	£
		Notes		
	Deferred income	15	70,000	94,163
	Trade creditors		24,168	42,054
	Other creditors		67,342	-
	Accruals		7,216	33,262
			168,726	169,479

AMR ACTION UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

15 Deferred income

	2024 £	2023 £
Arising from Oak Foundation	70,000	94,163

Deferred income is included in the financial statements as follows:

	2024 £	2023 £
Deferred income is included within:		
Current liabilities	70,000	94,163
Movements in the year:		
Deferred income at 1 January 2024	94,163	-
Released from previous periods	(24,163)	-
Resources deferred in the year	-	94,163
Deferred income at 31 December 2024	70,000	94,163

16 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 January 2024 £	Incoming resources £	Resources expended £	Transfers £	At 31 December 2024 £
	-	-	-	-	-
Antibiotic Resistance Breakers	27,224	-	(5,830)	(21,394)	-
Patient Support	12,441	1,429	(5,769)	-	8,101
Test Discs	44,090	(30,915)	(9,074)	-	4,101
Combined Research 2019 including Test Discs	26,379	-	(4,530)	(21,849)	-
Small Research Grants	93,397	38,044	(28,046)	20,059	123,454
Mutate Trial	54,957	(21,426)	-	(20,059)	13,472
TNL England	654	60,292	(59,239)	-	1,707
PhD student support	52,175	(2,175)	(25,000)	-	25,000
Reducing Antibiotic Prescribing	24,842	-	(3,575)	(21,267)	-
PSO Digital Transformation	25,275	-	(15,425)	-	9,850
Annual Lecture	35,452	19,634	(34,966)	-	20,119
Patient Videos	-	59,397	-	-	59,397
	396,886	124,279	(191,454)	(64,510)	265,201

AMR ACTION UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

16 Restricted funds

(Continued)

Previous year:	At 1 January 2023	Incoming resources	Resources expended	Transfers	At 31 December 2023
	£	£	£	£	£
Antibiotic Resistance Breakers	73,961	-	(46,737)	-	27,224
Patient Support	8,632	1,965	1,844	-	12,441
Test Discs	54,090	-	(10,000)	-	44,090
Combined Research 2019 including Test Discs	43,940	-	(17,561)	-	26,379
Small Research Grants	48,372	79,392	(34,367)	-	93,397
Mutate Trial	34,657	30,000	(9,700)	-	54,957
TNL England	40,865	-	(40,211)	-	654
TNL Wales	4,101	-	(4,101)	-	-
TNL Northern Ireland	2,443	-	(2,443)	-	-
PhD student support	52,175	25,000	(25,000)	-	52,175
Reducing Antibiotic Prescribing Student Programme	47,732 (126)	-	(22,890) 126	-	24,842 -
PSO Digital Transformation	-	34,850	(9,575)	-	25,275
Volunteer Network	-	1,600	(1,600)	-	-
Annual Lecture	-	35,532	(80)	-	35,452
	410,842	208,339	(222,295)	-	396,886

AMR ACTION UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

16 Restricted funds

(Continued)

Notes to restricted funds

Antibiotic Resistance Breakers (ARB) fund represents monies donated to fund the research into ARBs, this incorporates the Holbeck Charitable Trust funding as it was for the same cause.

Patient Support fund represents monies donated to fund a patient support officer whose role will be to develop a portfolio of patient support resources for people affected by antimicrobial resistance.

Patient Videos funds donated towards the production of video case studies to capture lived experiences and perspectives of those living or working with antibiotic resistance for use in campaigns to drive change.

Combined Research 2019 (2022 only) fund represents monies donated towards a specific application for funds from Antibiotics Research that identified expenditure across three programmes. Research into new antibiotic therapies, research into non-antibiotic alternatives (Diamond), and a small research grants scheme.

Test Discs funds represents monies donated towards the next stage of research. The manufacture and circulation to partners of a test disk sensitivity kit for further testing.

Combined Research 2019 Including Test Discs fund represents monies donated towards both of the above two funds.

Small Research Grants fund represents monies donated towards the small research grants programmes.

Mutate Trial fund represents monies donated for the next phase of the MUTATE research programme which is working with hospital microbiology labs in a round robin evaluation of cefepime / sulbactam test discs.

Big Give 2020 Combined Projects (2022 Only) fund represents monies donated through the online platform Big Give. Antibiotic Research identified the expenditure would cover patient support, original antibiotic resistance breakers and the small grants programmes.

TNL England fund represents a National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in England.

TNL Wales fund represents a National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in Wales.

TNL Northern Ireland fund represents a National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in Northern Ireland.

PhD student support fund represents monies donated by the Troutdale Trust to support a PhD student.

Reducing Antibiotic Prescribing through triaging using Point of Care testing fund represents monies donated for the Study Protocol Development and planning for the scaled up roll out of the study.

Student Programme represents monies donated to further engagement with university students across the UK through the development of a Student AMR Society Scheme and activities such as 'The Great University Science Quiz' (online).

PSO – Digital Transformation fund is towards the developing the patient support service through a digital transformation for a more efficient service.

Volunteer Network fund is to mobilise a network of people in different services to go out into the community and spread the work and engage with people to discuss the misuse and overuse of antibiotics and their resistance.

Annual Lecture fund represents monies received from Pfizer towards the costs of the 2024 annual lecture.

AMR ACTION UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

17 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 January 2024	Incoming resources	Resources expended	Transfers	At 31 December 2024
	£	£	£	£	£
General funds	56,445	282,610	(279,363)	64,510	124,202
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Previous year:	At 1 January 2023	Incoming resources	Resources expended	Transfers	At 31 December 2023
	£	£	£	£	£
General funds	30,237	268,726	(242,518)	-	56,445
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>

18 Analysis of net assets between funds

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
At 31 December 2024:			
Current assets/(liabilities)	124,202	265,201	389,403
	<u> </u>	<u> </u>	<u> </u>
	124,202	265,201	389,403
	<u> </u>	<u> </u>	<u> </u>
	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
At 31 December 2023:			
Current assets/(liabilities)	56,445	396,886	453,331
	<u> </u>	<u> </u>	<u> </u>
	56,445	396,886	453,331
	<u> </u>	<u> </u>	<u> </u>

19 Related party transactions

Telling Data Limited received £33,783.31 (2023: £27,500) for consultancy services and received £544.91 for expenses. Jonathan Pearce (Chief Executive of Antibiotic Research UK from 1 August 2022 to 26 July 2024) is the sole director of Telling Data Limited.

Accounts

**ANTIBIOTICS RESEARCH UK -
DEVELOPING NEW ANTIBIOTICS**

UNAUDITED ACCOUNTS

FOR THE YEAR ENDED

31 DECEMBER 2023

Charity number: 1157884

ANTIBIOTICS RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

I N D E X	P A G E
REFERENCE AND ADMINSTRATIVE INFORMATION	1
REPORT OF THE BOARD OF TRUSTEES	3
INDEPENDENT EXAMINER'S REPORT	14
STATEMENT OF FINANCIAL ACTIVITIES	15
BALANCE SHEETS	17
NOTES TO THE ACCOUNTS	18

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REFERENCE AND ADMINISTRATIVE INFORMATION

Charity Name	Antibiotic Research UK – Developing New Antibiotics
Charity Number	1157884
Principal address	Equinox House Clifton Park Shipton Road York YO30 5PN

TRUSTEES

The trustees of the charity are:

Mr S Dukes *	Chair
Mr N Stalbow	(Resigned 16 February 2023)
Professor C Bond	(Resigned September 2023)
Professor C Dowson	(Resigned September 2023)
Ms E Lyon*	(Resigned 14 February 2023)
Ms Cathy Tralau-Stewart	(Resigned September 2023)
Mr Phil Robinson *	Chair, Finance Committee (Resigned 31 May 2024)
Ms Carla Brown	(Resigned 17 May 2023)
Ms Fiona Russell *	
Ms Rosemary Howell	
Ms Ghada Zoubiane	(Appointed 21 February 2024)
Dr Christine Richardson	(Appointed 21 February 2024)
Dr Peter Kirkpatrick	(Appointed 21 February 2024)
Ms Clare Kerr	(Appointed 21 February 2024)
Ms Rose Gray	(Appointed 21 February 2024)

*Also, member/observer of the Finance Committee

Science Committee	Professor Chris Dowson	Interim Chair (Resigned September 2023)
	Dr Mike Allen	
	Dr Lloyd Czaplewski	(Resigned September 2023)
	Dr Tina Joshi	
	Professor Chris Schofield	
	Dr Joe Standing	
	Dr Mark Sutton	
	Dr David Wareham	
	Arlene Brailey	(Resigned 31 January 2023)
	Dr Chris Longshaw	(Resigned September 2023)

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REFERENCE AND ADMINISTRATIVE INFORMATION (Continued)

Public Education and Patient Support Committee

Professor Christine Bond	Chair (Resigned September 2023)
James Amos	
Carolyn Childs	(Resigned September 2023)
Professor Angharad Davies	(Tenure ended November 2023)
Dr Ryan Hamilton	(Resigned September 2023)
Rebecca Harmston	(Resigned September 2023)
Dr Roger Harrison	(Resigned September 2023)
Dr Charles Mitchell	(Resigned September 2023)
Dr Alison Staples	
Dr Neil Todd	
Dr Oliver Van Hecke	

Founding chairman Mr A Burgess

Chief Executive Jonathan Pearce

Patron The Most Revd & Rt Hon the Lord Archbishop of York, S Cottrell

ADVISORS

Principal Bankers Lloyds Bank PLC
2 Pavement
York
YO1 9UP

Independent Examiner Frances Howard FCA
Fortus Limited
Business Advisors and Accountants
Equinox House
Clifton Park Ave
Shipton Road
YO30 5NN

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) “Accounting and Reporting by Charities” in preparing the annual report and financial statements of the charity.

The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity’s governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published in October 2019.

WHO WE ARE AND WHAT WE DO

Antibiotic Research UK is a national organisation founded in 2014 which raises funds to support antibiotic research, provide information and support to patients and families affected by antimicrobial resistance, raise awareness about its work among the public and professionals, and influence and campaign for better national and international approaches to tackle antimicrobial resistance.

About antibiotic and antimicrobial resistance

Antibiotic resistance, that is when infectious bacteria become resistant to antibiotic treatment, is on the rise globally. Antimicrobial resistance (AMR) is a broader term that includes bacteria, viruses, fungi and parasites that develop resistance to antimicrobial medicines. An article published in The Lancet in 2022 estimated that, in 2019, 1.27 million people died globally directly from an antibiotic resistant infection (Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al, “Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis”, The Lancet, 2022; 399 (10325):629-5), a figure higher than people dying from HIV or malaria. This figure is alarming and whilst the highest number of deaths were in lower- and middle-income countries, COVID has shown us how quickly an infectious agent can spread around the globe.

According to the Institute for Health Metrics and Evaluation (IHME), in 2019 there were 7,600 deaths attributable to antimicrobial resistance (AMR) and 35,200 deaths associated with AMR (see “The burden of AMR in the UK” by IHME, University of Washington, University of Oxford and Global Research on Antimicrobial Resistance; available from <https://www.healthdata.org/antimicrobial-resistance/policy-briefings>). The IHME report also points out that the number of UK deaths from AMR is “higher than deaths from digestive diseases, diabetes and kidney diseases, other non-communicable diseases, unintentional injuries, and self-harm and interpersonal violence”.

In particular the IHME report goes on to highlight five key pathogens in the UK behind these figures (Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Enterococcus faecium and Streptococcus pneumoniae) that commonly caused bloodstream infections, peritoneal and intra-abdominal infections, urinary tract infections and pyelonephritis, lower respiratory infections and all related infections in the thorax, and lower respiratory infections and all related infections in the thorax.

Vision

A world free from death and suffering caused by drug-resistant infections.

Mission

To tackle the global threat of drug-resistant infections by:

- Driving forward innovative solutions to antibiotic resistance
- Improving the lives of people affected by drug-resistant infections
- Raising awareness of the impact of drug-resistant infections

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

Purpose

- To raise funds to support antibiotic research in the UK's universities, institutes, and organisations.
- To campaign, lobby and influence the public agenda for combating antimicrobial resistance.
- To provide educational materials about antibiotic resistance to the public and professionals.
- To develop a patient support and information network.

Values

- *Transparency* – We support world-class, peer-reviewed research focussed on bringing new antibiotic therapies to patients in a transparent and open way.
- *Quality* – We work to the highest ethical standards and are fully accountable to our stakeholders through open access to all we do.
- *Compliance* – We have put in place all the necessary governance procedures to comply with the necessary UK regulations and recommendations.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Constitution and trustee recruitment and appointment

Antibiotic Research UK was registered as a charitable incorporated organisation (CIO), with members, on 16 July 2014 and is governed by its constitution, this has been amended 24 October 2016, 29 November 2019 and 19 February 2024. Antibiotic Research UK has a wholly owned trading subsidiary, ANTRUK Enterprises Ltd, which is registered at Companies House (company registration no 10396024).

The work, management, finances and strategy of the charity are overseen by a Board of Trustees. The Trustees who held office during the financial year and at the date of the report are set out on page 1. The constitution requires there to be a minimum of three Trustees and a maximum of twelve Trustees in office at any one time. Trustees that are appointed at an annual general meeting (AGM) retire from office after a full term of three years, at the following AGM. However, Trustees that are appointed directly by the Board of Trustees in between AGMs must step down at the next AGM, but can stand for re-election at that AGM, and if so re-elected, their first three-year term of office starts at that point. A Trustee can seek re-election for a further three-year term of office but not a third term without an interval of a year.

Purpose

The charity's purposes are set out in its constitution, as follows:

“... to protect and promote the health of the public, in particular by sponsoring research into the diagnosis, treatment and cure of antibiotic-resistant bacterial infectious diseases, ensuring responsible and sustainable development and deployment of the findings of such research, and raising awareness through public-facing activities and the promotion of networks to share experience of such matters.”

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

STRUCTURE, GOVERNANCE AND MANAGEMENT

Public benefit

The organisation's work delivers public benefit by funding and developing research to address the issue of antibiotic and antimicrobial resistance, which already claim thousands of lives each year nationally and internationally. The number of deaths will continue to increase, unless new antibiotics are discovered and brought to market, and unless the use of new and existing antibiotics is better managed and stewarded so as to prolong their use and increase their efficacy.

The organisation also provides invaluable support and assistance to those directly affected by antimicrobial resistance, as well as to the healthcare practitioners working with them. Reliable, evidence-based information and peer support helps them navigate their conditions and improve their longer term outcomes. As part of our business planning processes, we review our aims and objectives each year, which includes looking at what we have achieved previously, and how our activities have benefited those groups of people we are set up to help. We have referred to the Charity Commission's guidance on public benefit when reviewing our aims and objectives, and in planning our work for the future.

Board and management operations and structure

Board of trustees

The Board of Trustees meets at least four times a year to review the organisation's work, finances and services, and to agree the strategic goals for the charity. The Chief Executive Officer attends all meetings. The Board is also establishing a process to review its own operation, effectiveness and governance. A Finance Committee, chaired by the Treasurer and comprising at least two other Trustees, meets quarterly to monitor and scrutinise the charity's financial strategy and operations, and makes recommendations to the full Board of Trustees.

The Board also operated two other committees during 2023, as follows:

- **Science Committee**

The Science Committee is responsible for commissioning and monitoring the charity's scientific research programmes. The Science Committee consists of a number of experienced antimicrobial scientists and clinicians. Full membership details can be found on page 1.

- **Public Engagement and Patient Support Committee**

The Public Engagement and Patient Support Committee (PEPS) is focused on increasing awareness about the importance of tackling drug-resistance amongst professionals and the public, and on providing support and guidance to the charity's patient support services. The Committee consists of a range of individuals including clinicians, AMR scientists, public health experts, education professionals and individuals to provide a patient perspective. Full membership details can be found on page 2.

However, during 2023 as part of a full governance review carried out by the Board of Trustees, and in consultation with the committee members and the charity's staff, it was decided to replace the charity's existing committee structure with a single new committee, called the Science, Policy and Education Committee, with the committee's purpose being to provide assistance and assurance to the Board on the following matters:

It was also acknowledged during the governance review that the charity needed to supplement existing committee expertise and experience with additional areas of specialism to reflect the wider range of work and influence contained within future organisational strategies. While the new committee included some members from the previous structure (and came into operation in March 2024, during 2024 the organisation began recruiting additional members to ensure that the full range of the following experience and expertise was represented within the committee:

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

Board and management operations and structure (continued)

- Scientific research in the fields of antibiotic resistance, infectious diseases and/or drug development.
- Clinical practice in the diagnosis, treatment and care of infectious diseases, including antibiotic-resistant infections, whether in primary, secondary or tertiary care services, and especially in the fields of urinary tract infections (UTIs), respiratory tract infections, skin/soft tissue infections, sexually transmitted infections and bloodstream infections.
- Personal experience as a patient or carer.
- Antimicrobial stewardship.
- Infection management and prevention.
- Epidemiology.
- Pharmacy, whether in community, primary, secondary or tertiary care settings.
- Dentistry.
- Veterinary science/practice.
- Public health.
- Public affairs/policy experience.
- Public education campaigns/initiatives.
- Journalism, communications and PR initiatives.
- Health economics.
- Research project management.

Recruitment and appointment of new trustees

An annual review of the recruitment needs of the Board of Trustees is carried out under the leadership of the Chair, including an audit of the current knowledge, experience, skills and abilities, and how they will be affected by any trustee departures in the future. Any Trustee vacancies are advertised nationally, and via relevant professional and organisational networks, including the charity's own supporter base, depending upon the expertise and specialisms required. Applicants are shortlisted against the criteria in the person specification for the role of Trustee, including any specific qualities highlighted during the above audit. Shortlisted applicants are invited for interview by at least two Trustees, one of whom will be the chair. Shortlisted applicants are only appointed where they have the necessary skills and qualities to contribute effectively to the charity's governance and development. All new Trustees receive thorough induction and training, which includes information about the organisation's constitution, accounts, financial reports and minutes of previous Trustees' meetings.

Management and organisation

Day-to-day operation of the charity, and strategy implementation, is delegated to the chief executive officer, who is supported by a small team of staff, working in the fields of grant and charity administration, patient support, media, press and PR management, fundraising and financial management.

Risk assessment and management

The organisation has adopted a risk management policy which lists the potential risks to the charity, with an indication of the level of risk. The main areas of identified risk are in relation to:

- Regulatory and compliance risks arising from the organisation's research, patient support and fundraising work.
- Lack of investment in ICT hardware, software and systems, including IT security which impact on business efficiency, business opportunities and business continuity.
- Adequate finances and fundraising, due to the external economic situation, changes in funding trends and priorities, and the need to manage committed research expenditure, alongside general organisational resources.
- Operational risks due to the organisation's reliance on a small number of individuals.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

Risk assessment and management (continued)

To address these risks, effective management measures and controls have been put in place by the Trustees, including:

- The establishment, review and monitoring of a strong governance framework of organisational policies, standard operating procedures (SOPs) and terms of reference that govern the organisation's work, particularly in the fields of research, patient support, information development and fundraising. A governance committee was established in 2022 to oversee this area of the organisation's work, which was completed in 2023. The charity is registered with the Association of Medical Research Charities (which carries out an online audit every five years) and the Fundraising Regulator.
- Ensuring Trustees, committee members and staff have solid experience and expertise in their fields.
- The recommendations from the external audit and review of the charity's ICT systems carried out in late 2022/early 2023, was implemented during the second half of 2023 and the first half of 2024, bringing additional security and improvements to organisational efficiency, capacity and collaboration.
- Strong financial oversight from the Finance Committee and Board of Trustees, including maintaining a strong reserves policy and not committing to project expenditure or research commitments until the funds have been secured and banked.
- Using consultant employment contracts, supplier contracts and legal agreements to secure relevant expertise and advice, as well as providing for staffing shortfalls, while also reviewing the organisation's staffing model and structure.
- Maintaining third-party liability and indemnity insurance.

Management and organisation

Day-to-day operation of the charity, and strategy implementation, is delegated to the chief executive officer, who is supported by a small team of staff, working in the fields of grant and charity administration, patient support, media, press and PR management, fundraising and financial management.

ACHIEVEMENTS AND PERFORMANCE

Introduction

Antibiotic resistance remains a major global health issue, on a par with climate change, but receiving far less attention nationally and internationally. However, 2023 seemed like a particularly important year in the battle against antibiotic resistance, with increasing media coverage and public awareness, and the launch or start of important new initiatives and activities. For instance, in the UK alone, we were pleased to see (and support during the second half of 2023) the government working on its new National AMR Action Plan (the final version of which was officially published in May 2024). Furthermore, we were involved in the work and preparation behind the government's £30m PACE (Pathways to Antimicrobial Efficacy) research initiative announced towards the end of last year (see further below). Although on one level this research funding is a "drop in the ocean", it is a welcome step forward at time when the biotech sector and university researchers working in the field of antimicrobial resistance (AMR) are under increasing threat and pressure. We were also pleased to learn that a couple of our previous research projects, where we provided seed funding or funding for proof of concept, were now being considered for a major, longer-term PACE award – proof, if it were needed, of the importance of our work in supporting early career research in AMR at a time when there is a "brain drain" in the field, with young academics finding it hard to carve out a career, while other clinical research areas, such as cancer, attract much more funding and profile.

In summary

In simple terms, our key organisational achievements during 2023 were:

- 209 individuals living with resistant infections and their families received personalised support and information from our Patient Support Team, via phone, email, plus our new peer-to-peer Zoom sessions.
- Over 570,000 people visited our web site to access trusted information.
- Three new research programs in the field of UTIs were funded, supporting early career researchers.
- Approximately 50 newly qualified pharmacists were trained with sessions on antibiotic resistance and patient perspectives, and over 2,000 GPs reached via presentations at two leading GP events (GP Guidelines Live in London and the Royal College of GPs Annual Conference in Glasgow).

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

In summary (continued)

What this led to in terms of impact was:

- Patients telling us about the positive impact our support and information made, helping them better understand their condition and empowering them to work effectively with health care practitioners.
- Following this, some patients choosing to become Antibiotic Research UK ambassadors, sharing their powerful stories with the public and healthcare practitioners to raise awareness.
- Seven peer reviewed journal publications reporting new discoveries (where research was funded by us).
- Six further academic publications citing our work or information, demonstrating growing reach and authority within the research community.

In specific themes

Within our overall organisational goals, following a strategic review in 2022 we decided to focus our work in 2023 and 2024 on four key themes:

- **Urinary Tract Infections (UTIs)** – prioritising research and information/support services for these patient communities, which make up the overwhelming proportion of the people we help.
- **Supportive communities** – building our patient, supporter and influencer communities, so we can better provide help to more people.
- **Technology and modernisation** – utilising digital technology to improve the work we do, provide better services and reach more people.
- **Knowledge and communication** – learning from our research programmes and our direct understanding of patient experience, so that we disseminate these insights and education via our online hubs, events and training programmes.

Urinary tract infections

The PACE initiative mentioned above is being run by the Medicines Discovery Catapult, LifeArc and Innovate UK, and our Chief Executive Officer, Jonathan Pearce, was pleased to accept a position on PACE's Strategic Advisory Committee, which oversees the research priorities and outcomes, while one of our newly appointed Trustees, Dr Ghada Zoubiane, will be the Committee's Chair. Our relationship with the PACE initiative is such that we expect to be a key organisation in providing personal and patient experience to the research programme, particularly in the field of UTIs (see further below).

Supportive communities

Furthermore, we have been able to build relationships with other charities working in the UTI field so that we can work together to tackle the diagnostic and treatment difficulties faced by the millions of predominantly older women. In particular, The Urology Foundation and Bladder Health UK have agreed to partner with us on running a James Lind Alliance(JLA)/National Institute of Health Research research priority-setting partnership to identify the main research “unknowns” and uncertainties for UTI patients, so that future research across the sector can be more effectively prioritised on the basis of what patients themselves and their clinicians actually need. We were pleased to launch this JLA partnership at our ground-breaking conference on UTIs held in March 2024 at the Wellcome Collection in London. The conference itself also succeeded in bringing together an audience of over 150 people, representing a balanced mix of patients, clinicians, researchers and industry professionals, to hear from leading patient and professional experts on the key barriers to addressing chronic and complex UTIs, the beginnings of a community of support that will help us drive change and improvement in the UTI field.

Technology and modernisation

Over the last 12 months, the charity has gone through a major overhaul of its IT infrastructure in two particular respects:

- **Website redevelopment** – following a thorough procurement process in the later part of 2023, we agreed to partner with leading website agency, Fat Beehive, to redevelop our website. The project began in January 2024 and the new website is planned to launch in July 2024.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

Technology and modernisation (continued)

- **IT infrastructure** – we have invested in our IT and communication systems so that we can work more efficiently and effectively and with a stronger digital focus. This programme of our work has seen a migration of our email systems into a Sharepoint/Microsoft 365 environment (which itself went through a modernisation and upgrade) so that all our systems are interconnected, enabling better organisation and sharing of our information and data, as well as supported improved project management work and communication.

Knowledge and communication

We have made less progress in this area than anticipated and will be making this more of a priority in our work in the second half of 2024. However, we are proud of the fact that we were able to launch a Medical Writing Project in September, which has continued into 2024, and is planned to complete with the launch of our new website in 2024. Using an expert medical writer and lay/professional reviewers, the project has focused on a digital first overhaul of all our written information and content on antibiotics, antibiotic resistance, related multi-drug resistant infections and associated diseases, as well as antibiotic stewardship. This has also included the creation of a lot of new content and material and we are confident that the completed project will deliver one of the leading, lay/patient friendly digital resources for antimicrobial resistance.

Patient Support

Throughout 2023, our Patient Support Service remained focused on supporting individuals (and their families) in resolving unanswered questions about infection and antibiotic resistance. The number of new enquiries decreased slightly in 2023 to 209 (compared to 272 in 2022), largely a consequence of changes to how we measure and monitor new contacts and follow-up enquiries. By early 2023 we had responded to a spike in enquiries due to the outbreak in Strep A in children in the UK. While the majority of enquiries to our Patient Support Service continue to be about UTIs (over 50%), the number of enquiries about antibiotic allergies is growing (15% in 2023). We continued to provide vital support to those affected by resistant infections and we were able to start testing online support groups alongside our traditional phone and email enquiry services, while also updating and expanding the range of healthcare information we have available online or for use in healthcare settings.

We also succeeded with our patient support outreach, engagement and advocacy work during 2022, working with the NHS AMR Diagnostics Board (of which our CEO is a member) and then with the Board's high profile work on developing target profiles for industry to develop new diagnostic tools for certain types of multi-drug resistant. We also continued our constructive partnership with Well Pharmacy during the year, where we were pleased to provide continuing professional development training to the chain's community pharmacy staff.

We were also pleased to attend and present at a number of national events, including the major GP Guidelines Live conference, and the Royal College of GPs Annual Conference in Glasgow, in order to raise awareness of antibiotic resistance and to provide insight on the patient perspective.

Raising awareness

Antibiotic Research UK is committed to raising awareness about AMR, in particular by bringing insights from patients and their families and friends to a wider audience. In 2023 the theme for the World Health Organisation-led World AMR Awareness Week in November was *Preventing Antimicrobial Resistance Together*. We presented at external events such as AMR Relay and Guidelines Live, turned our logo blue (#goblue campaign), and encouraged our partners to do the same. Several companies chose to highlight us and raise awareness with us on social media. This is hugely important as it helps amplify messages and raises awareness of our support services for patients and professionals, while demonstrating our corporate partners' values and commitments. Some companies held workplace cake sales in aid of the charity, involving and engaging staff, creating a positive workplace culture.

Our website traffic continued to grow during 2023. There were over 570,000 visitors to our website, a sign of the new for trusted information on antibiotic resistance, something that we have built into our Medical Writing Project (see above), the fruits of which we look forward to seeing in 2024.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

Raising awareness (continued)

During the year we succeeded in maintaining good media coverage and were able to secure key articles in both the mainstream and trade press. Our communications and campaigns were supported by our vibrant social media activity and by the end of 2023, we grew our Facebook following to 1,580 followers, Twitter to 6,314, Instagram to 999 and LinkedIn to 5,704.

Fundraising

Although the current fundraising environment continues to be challenging with donations affected by the high inflation, the cost of living crisis and national economic challenges, we were pleased to record the highest ever income generation levels in the charity's history. In particular we were pleased to receive two generous multi-year grants, the first from the Oak Foundation to support capacity-building within the charity, and the second from the National Lottery Fund, supporting the continuation of our Patient Support Service for the next three years. As always, we are enormously grateful to those who donated and volunteered on our behalf. Without their support we would not be able to continue our vital work.

Fundraising highlights in 2023 included:

- Just over £237,000 from The National Lottery Reaching Communities to fund our Patient Support Service for three years from 2024 to 2026 (inclusive).
- Over £400,00 from the Oak Foundation over three years from 2023 to 2026 to support organisational capacity-building.
- £50,000 from the Garfield Weston Foundation.
- Approximately £135,000 secured to fund our research programme over 1-2 years from a number of generous Trusts and Foundations.
- Approximately £10,000 raised by the York Fundraising Group from an event at Hovingham Hall, North Yorkshire.
- Over £100,000 from a range of corporate sponsorship and grants.

FINANCIAL REVIEW

The consolidated gross income for the year was £477,064 (2022: £399,824).

The consolidated net movement in funds for the year was a surplus of £12,255 (2022: surplus of £250).

Going concern

Management works to an annual budget and has prepared a forecast to the end of December 2024, along with outline projections for 2025. These are used by management to ensure the organisation has sufficient funds in place to manage working capital in both the short term and longer term and enables the planning of resource allocation, organisational strategy, sustainability, and development.

Management has identified strong fundraising performance as crucial to positive cash flow management, particularly in relation to unrestricted funding. Fundraising plans and activities and future expenditure management have been reviewed, so as to better understand the impact of varying cashflows on the solvency of the organisation. Budgets have been set in line with the parameters in that review and are sufficient to ensure the organisation has adequate funds to meet its cash flow obligations to the end of 2025. While the financial and fundraising measures that were implemented in 2023 have enabled stability in the charity's finance and strong financial control, including contingency plans to manage any fundraising shortfalls, it remains challenging to grow unrestricted reserves at the speed we would like. Ongoing monitoring and review continue to be required to ensure sustainability.

With these measures in place, trustees are confident about the organisation's ability to continue in operation for at least twelve months from the date of the financial statements. On this basis, together with the unrestricted funding received in the first six months of 2024, the Board has approved the preparation of the financial statements on the going concern basis.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

Reserves policy

The trustees aim to maintain a minimum of free reserves equal to 3 months' core expenditure (approximately £60,000). Any funds over this sum will be used to fund the charity's objects. The year-end level of free reserves was £54,595 (2022: £30,237). As noted above, organisational plans have been implemented to grow unrestricted reserves, including building a predictable and reliable funding base from individual and regular giving, as well as with community and corporate support, and through refocusing some of our fundraising priorities on essential expenditure related to our core mission.

PLANS FOR FUTURE PERIODS

During 2023, the Board maintained the organisation's three overarching goals set out in our original five-year strategy as approved in 2021, but within those goals it was agreed as part of a strategic review in late 2022, that we would prioritise and focus our work, particularly on the needs of patients UTIs that over 50% of our support services. Accordingly, we continue to be guided by the following objectives:

Goal 1: Drive forward innovative solutions to drug-resistant infections

Through collaboration, we will advance research by supporting the completion of our Mutate research project to identify one viable combination therapy that can be put into clinical use. We will also support underfunded areas of antimicrobial (AMR) research and progress the next generation of researchers in the AMR field.

We will do this by:

Short Term (1–3 years)

- Continuing to run the small research grants/career development awards programme, prioritising grants for basic research and/or health sciences projects, particularly focussing on seed funding and early-career projects for innovative therapeutic (small molecule, biological including phage therapy) approaches to UTI infections (ideally oral) and improved routine diagnostics
- Seeking out funding partnerships to build on existing UTI-based research projects, including the investigation of possible antibiotic combination therapies, alternatives to antibiotics, or improved stewardship initiatives
- Seeking out partnerships for AMR projects related to the behavioural, social sciences and/or applied health sciences (eg, a pilot trial in antibiotic stewardship), increasing the scope for collaboration with policymakers and healthcare providers
- Developing and delivering an education and training programme for both healthcare practitioners and patient communities, thus creating and supporting networks in both aspects of our work
- Run a priority-setting partnership to determine patient-led research priorities in the field of UTIs

Goal 2: Improve the lives of people affected by drug-resistant infections

We aim to improve the lives of patients and their families by acting as a source of trustworthy information. We will work to reach more patients and build the strength of this patient community so that their collective voice can be heard and to ensure that our services best fit their needs.

We will do this by:

Short Term (1–2 years):

- Developing the patient support service to increase capacity and resources in response to need, including:
 - Formalising use of and access to telephone and digital support services.
 - Creating online peer support networks.
 - Establishing clear, effective systems for the evaluation of our support services.
 - Providing information and support to meet the needs of a diverse population of service users.
 - Establish evaluation systems.
 - Developing a digital-first set of patient information that can be accessed via our website and used by patients, the public and professionals alike.
- Developing a network of volunteers and volunteer groups, focused on providing or signposting towards support in local communities, raising awareness and fundraising.

REPORT OF THE BOARD OF TRUSTEES

PLANS FOR FUTURE PERIODS (continued)

Goal 3: Raise awareness about the impact of drug-resistant infections

We will work to raise the profile of the human impact of drug-resistant infections. We will partner with other organisations to run awareness campaigns and lobby government to drive the policy changes needed to reduce the spread of drug-resistant infections.

We will do this by:

Short Term (1–2 years):

- Developing an influencing, lobbying and campaigning programmes to promote a defined list of key policy/practice asks related to speeding up the AMR agenda and holding the government and other AMR stakeholders to account
- Increasing engagement with universities by helping establish undergraduate AMR societies (or coordinate with existing science and health societies); supporting these societies to organise outreach events for both the university and local communities
- Developing an ambassador programme (patient, community fundraising, healthcare professionals and high-profile/celebrity)
- Develop a corporate partnership package

Long Term (2+ years)

- Investigating opportunities to work with similar national organisations, grow globally and become a leading advocate for the patient voice of drug-resistant infections worldwide.

Behind each of these goals and priorities we have identified a set of enablers, milestones and performance indicators, which we have designed to guide our approaches to potential funders and supporters. In order to achieve our goals, we need to reach more people and organisations willing to support us in the fight against antibiotic resistance. Key to building that platform of financial support are:

- Building a reliable and predictable base of fundraising income from individual gifts and regular givers
- Acquisition of new donors/supporters
- Corporate support.

As many of these objectives are due to complete in the near future, the charity has also embarked on a major strategic review during early 2024, with the support of the Oak Foundation, which will clarify and confirm the charity's long-term plans, and how it will achieve them, underpinned by a theory of change. It is a challenging task, but an important one. We hope you will join us in tackling one of the most important health issues of modern times.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

TRUSTEES' RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS

The trustees are responsible for preparing the Report of the Board of Trustees' and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of income and expenditure of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2019 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees on 24 July 2024 and signed on their behalf by:



.....
Mr S Dukes – Chair

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 December 2023 which comprise the statement of financial activities, balance sheet and relevant notes.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the charity's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Frances Howard

Frances Howard FCA
Fortus Limited
Business Advisors and Accountants
Equinox House
Clifton Park Ave
Shipton Road
YO30 5NN

25 July 2024

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	2023 Unrestricted funds £	2023 Restricted funds £	2023 Total funds £	2022 Total funds £
INCOME					
Donations and legacies:					
Donations and grants	2	41,856	42	41,898	66,704
Charitable activities		206,031	208,297	414,328	294,033
Other trading activities:					
Membership fees		3,480	-	3,480	3,745
Fundraising events		15,132	-	15,132	35,342
Other		2,226	-	2,226	
Total income		268,725	208,339	477,064	399,824
EXPENDITURE					
Raising funds					
Fundraising costs	3	115,522	-	115,522	84,753
Charitable activities					
Charitable activities	4	126,992	222,295	349,287	314,821
Total expenditure		242,514	222,295	464,809	399,574
Net (expenditure)/ income		26,211	(13,956)	12,255	250
Transfer between funds	8,9	-	-	-	-
Net movement in funds		26,211	(13,956)	12,255	250
Fund balance brought forward at 1 January 2023		30,237	410,842	441,079	440,829
Fund balance carried forward at 31 December 2023	8,9	56,448	396,886	453,334	441,079

All income and expenditure derives from continuing activities.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2023

PRIOR YEAR

	Notes	2022 Unrestricted funds £	2022 Restricted funds £	2022 Total funds £
INCOME				
Donations and legacies:				
Donations and grants	2	56,044	10,660	66,704
Charitable activities		107,278	186,755	294,033
Other trading activities:				
Membership fees		3,745	-	3,745
Fundraising events		33,934	1,408	35,342
Total income		201,001	198,823	399,824
EXPENDITURE				
Raising funds				
Fundraising costs	3	80,108	4,645	84,753
Charitable activities				
Charitable activities	4	291,470	23,351	314,821
Donated services		-	-	-
Total expenditure		371,578	27,996	399,574
Net (expenditure)/ income		(170,577)	170,827	250
Transfer between funds	8,9	165,466	(165,466)	-
Corporation tax receivable		-	-	-
Net movement in funds		(5,111)	5,361	250
Fund balance brought forward at 1 January 2022		35,348	405,481	440,829
Fund balance carried forward at 31 December 2022	8,9	30,237	410,842	441,079

All income and expenditure derives from continuing activities.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

BALANCE SHEETS AT 31 DECEMBER 2023

	Notes	Consolidated		Charity only	
		2023 £	2022 £	2023 £	2022 £
FIXED ASSETS					
Investments	5	-	-	1	1
CURRENT ASSETS					
Debtors and prepayments	6	7,625	561	7,954	561
Cash at bank and in hand		615,185	463,366	614,855	462,816
		<u>622,810</u>	<u>463,927</u>	<u>622,809</u>	<u>463,377</u>
LIABILITIES: Amounts falling due within one year	7	(169,476)	(22,848)	(169,476)	(22,299)
		<u>453,334</u>	<u>441,079</u>	<u>453,333</u>	<u>441,078</u>
NET CURRENT ASSETS					
		<u>453,334</u>	<u>441,079</u>	<u>453,334</u>	<u>441,079</u>
NET ASSETS		<u><u>453,334</u></u>	<u><u>441,079</u></u>	<u><u>453,334</u></u>	<u><u>441,079</u></u>
THE FUNDS OF THE CHARITY					
Unrestricted funds	9	54,595	30,237	54,595	30,237
Restricted funds	8	398,739	410,842	398,739	410,842
		<u>453,334</u>	<u>441,079</u>	<u>453,334</u>	<u>441,079</u>
TOTAL CHARITY FUNDS		<u><u>453,334</u></u>	<u><u>441,079</u></u>	<u><u>453,334</u></u>	<u><u>441,079</u></u>

Approved by the trustees on 24 July 2024 and signed on their behalf by:



Mr S Dukes - Chair

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2023

1. ACCOUNTING POLICIES

Basis of accounting

Antibiotic Research UK – Developing New Antibiotics is a charitable incorporated organisation in England. The address of the registered office is given in the charity information within the trustees' report of these financial statements.

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011, and UK Generally Accepted Accounting Practice.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are prepared in sterling which is the functional currency of the charity.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

Group financial statements

These financial statements consolidate the results of the charity and its wholly owned subsidiary ANTRUK Enterprises Limited on a line by line basis.

The gross income of the charity for the year was £477,064 and the result of the charity for the year was net surplus of £12,255.

Going Concern

The charity's financial statements are prepared on a going concern basis on the grounds that current and future sources of funding or support will be more than adequate for the charity's needs. The trustees have considered a period of twelve months from the date of approval of the financial statements and believe that no further disclosures relating to the charity's ability to continue as a going concern need to be made in the financial statements.

Fund accounting

Unrestricted funds are funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

Restricted funds are donations which the donor has specified are to be solely used for particular areas of the charity's work or for specific projects being undertaken by the charity.

Income

All income is included in the statement of financial activities when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donated services are accounted for at a reasonable estimate of their value to the charity and are included in the statement of financial activities as income when receivable.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2023

1. ACCOUNTING POLICIES (Continued)

Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Raising funds relates to costs incurred directly to generate donations. Charitable expenditure comprises those costs incurred by the charity in pursuit of its charitable object. Grants payable are charged in the year when the offer is conveyed to the recipient.

Tangible fixed assets and depreciation

Individual fixed assets costing £500 or more are capitalised at cost. Currently Antibiotic Research UK has no tangible fixed assets.

Debtors

Trade and other debtors are recognised at the settlement amount due. Prepayments are valued at the amount net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2. DONATIONS AND GRANTS

	2023 Unrestricted Funds £	2023 Restricted Funds £	2023 Total Funds £	2022 Unrestricted Funds £	2022 Restricted Funds £	2022 Total Funds £
Donations	13,115	-	13,115	12,992	-	12,992
Gift Aid	5,556	-	5,556	13,316	-	13,316
Online giving	23,185	42	23,227	29,736	10,660	40,396
	41,856	42	41,898	56,044	10,660	66,704

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2023

3. RAISING FUNDS EXPENDITURE

	2023 Unrestricted Funds £	2023 Restricted Funds £	2023 Total Funds £	2022 Unrestricted Funds £	2022 Restricted Funds £	2022 Total Funds £
Fundraiser fees	104,510	-	104,510	77,810	4,615	82,425
Fundraising expenses	11,012	-	11,012	2,298	30	2,328
	<u>115,522</u>	<u>-</u>	<u>115,522</u>	<u>80,108</u>	<u>4,645</u>	<u>84,753</u>

4. CHARITABLE ACTIVITIES

	2023 Unrestricted Funds £	2023 Restricted Funds £	2023 Total Funds £	2022 Unrestricted Funds £	2022 Restricted Funds £	2022 Total Funds £
Trading subsidiary 5	221	-	221	185,441	-	185,441
Direct project grants	-	165,905	165,905	-	-	-
Other Direct project costs	-	18,120	18,120	-	-	-
Patient support costs	-	27,277	27,277	-	5,364	5,364
Legal and professional fees	41,486	5,883	47,369	54,754	4,921	59,675
Consultancy fees	57,000	-	57,000	26,935	4,546	31,481
Accountancy	10,413	-	10,413	9,146	-	9,146
Printing, postage and stationery	623	3	626	375	586	961
Website and IT	5,408	2,240	7,648	6,642	90	6,732
Phone and internet	240	-	240	198	-	198
Computer and software	7,169	243	7,412	4,008	-	4,008
Insurance	945	-	945	407	-	407
Travel and subsistence	1,998	134	2,132	1,386	224	1,610
Bank and CAF charges	818	-	818	1,293	-	1,293
Recruitment costs	645	890	1,535	885	-	885
Annual lecture costs	-	-	-	-	4,494	4,494
Student engagement sponsorship work	-	1,600	1,600	-	3,126	3,126
Sundry expenses	26	-	26	-	-	-
	<u>126,992</u>	<u>222,295</u>	<u>349,287</u>	<u>291,470</u>	<u>23,351</u>	<u>314,821</u>

Accountancy fees includes payments to the independent examiner of £2,910 (2022: £2,826) for the independent examination and £440 (2022: £960) for other accountancy services.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2023

5. TRADING SUBSIDIARY

The wholly owned trading subsidiary, ANTRUK Enterprises Ltd (company number: 10396024), which was incorporated in England and Wales on 27 September 2016, provides funding to research projects concerning antibiotics. The charity owns the entire issued share capital of 1 ordinary share of £1. A summary of the trading results is shown below. Monies was granted from the charity to the trading subsidiary to fund research projects.

The activities of the subsidiary are being transferred to the charity and therefore are discontinuing within the subsidiary but continuing within the group.

Summary profit and loss account

	2023 £	2022 £
Research costs and administration expenses	(221)	(185,441)
Income from group undertakings	221	183,977
Corporation tax (payable)/ repayable	-	-
Retained in subsidiary	-	(1,464)
The assets and liabilities of the subsidiary were:		
Current assets	1	5,109
Creditors: amounts falling due within one year	-	(5,108)
Total net assets	1	1
Aggregate share capital and reserves	1	1

Last year included within research costs were grants made to 6 institutions for £101,437. There were no grants made to individuals. No grants were made in the year.

6. DEBTORS

	2023 Group £	2022 Group £	2023 Charity £	2022 Charity £
Prepayments and accrued income	7,625	561	7,625	561
Amounts due from group undertaking	-	-	329	
	7,625	561	7,954	561

7. CREDITORS DUE WITHIN ONE YEAR

	2023 Group £	2022 Group £	2023 Charity £	2022 Charity £
Accounts payable	42,054	6,428	42,054	6,428
Accruals	33,260	16,420	33,260	11,312
Deferred Income	94,162	-	94,162	4,559
	169,476	22,848	169,476	22,299

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2023

• **2023**

	At 1.1.23 £	Income £	Expenditure £	Transfer £	At 31.12.23 £
Antibiotic Resistance Breakers	73,961	-	(46,737)	-	27,224
Patient Support	8,632	1,965	1,844	-	12,441
Test Discs	54,090	-	(10,000)	-	44,090
Combined Research 2019 including Test Discs	43,940	-	(17,561)	-	26,379
Small Research Grants	48,372	79,392	(34,367)	-	93,397
Mutate Trial	34,657	30,000	(9,700)	-	54,957
TNL England	40,865	-	(40,211)	-	654
TNL Wales	4,101	-	(4,101)	-	-
TNL Northern Ireland	2,443	-	(2,443)	-	-
PhD student support	52,175	25,000	(25,000)	-	52,175
Reducing Antibiotic Prescribing Student Programme	47,732 (126)	-	(22,890) 126	-	24,842 -
PSO Digital Transformation	-	34,850	(9,575)	-	25,275
Volunteer Network	-	1,600	(1,600)	-	-
Annual Lecture	-	35,532	(80)	-	35,452
	<u>410,842</u>	<u>208,339</u>	<u>(222,295)</u>	<u>-</u>	<u>396,886</u>
	<u><u>410,842</u></u>	<u><u>208,339</u></u>	<u><u>(222,295)</u></u>	<u><u>-</u></u>	<u><u>396,886</u></u>
	2022				
	At 1.1.22 £	Income £	Expenditure £	Transfer £	At 31.12.22 £
Antibiotic Resistance Breakers	68,879	-	-	5,082	73,961
Patient Support	13,097	15,620	(6,269)	(13,816)	8,632
Combined Research 2019	54,419	-	-	(54,419)	-
Test Discs	54,090	-	-	-	54,090
Combined Research 2019 including Test Discs	62,824	-	-	(18,884)	43,940
Small Research Grants	25,000	19,710	-	3,662	48,372
Mutate Trial	8,457	26,200	-	-	34,657
Big Give 2020 programmes	18,075	-	-	(18,075)	-
Combined Research 2020 including mutate trial & non-antibiotic alternatives	19,049	-	-	(19,049)	-
Combined Research 2021	27,795	-	-	(27,795)	-
TNL England	9,135	57,582	(9,106)	(16,746)	40,865
TNL Wales	4,101	-	-	-	4,101
TNL Northern Ireland	2,443	-	-	-	2,443
PhD student support	27,500	27,500	(325)	(2,500)	52,175
Reducing Antibiotic Prescribing Student Programme	10,617 -	38,461 3,750	(130) (3,126)	(1,216) (750)	47,732 (126)
Annual Lecture	-	10,000	(9,040)	(960)	-
	<u>405,481</u>	<u>198,823</u>	<u>(27,996)</u>	<u>(165,466)</u>	<u>410,842</u>

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2023

8. RESTRICTED FUNDS (Continued)

Antibiotic Resistance Breakers (ARB) fund represents monies donated to fund the research into ARBs, this incorporates the Holbeck Charitable Trust funding as it was for the same cause.

Patient Support fund represents monies donated to fund a patient support officer whose role will be to develop a portfolio of patient support resources for people affected by antimicrobial resistance.

Combined Research 2019 (2022 only) fund represents monies donated towards a specific application for funds from Antibiotics Research that identified expenditure across three programmes. Research into new antibiotic therapies, research into non-antibiotic alternatives (Diamond), and a small research grants scheme.

Test Discs funds represents monies donated towards the next stage of research. The manufacture and circulation to partners of a test disk sensitivity kit for further testing.

Combined Research 2019 Including Test Discs fund represents monies donated towards both of the above two funds.

Small Research Grants fund represents monies donated towards the small research grants programmes.

Mutate Trial fund represents monies donated for the next phase of the MUTATE research programme which is working with hospital microbiology labs in a round robin evaluation of cefepime / sulbactam test discs.

Big Give 2020 Combined Projects (2022 Only) fund represents monies donated through the online platform Big Give. Antibiotic Research identified the expenditure would cover patient support, original antibiotic resistance breakers and the small grants programmes.

TNL England fund represents a National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in England.

TNL Wales fund represents a National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in Wales.

TNL Northern Ireland fund represents a National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in Northern Ireland.

PhD student support fund represents monies donated by the Troutdale Trust to support a PhD student.

Reducing Antibiotic Prescribing through triaging using Point of Care testing fund represents monies donated for the Study Protocol Development and planning for the scaled up roll out of the study.

Student Programme represents monies donated to further engagement with university students across the UK through the development of a Student AMR Society Scheme and activities such as 'The Great University Science Quiz' (online).

PSO – Digital Transformation fund is towards the developing the patient support service through a digital transformation for a more efficient service.

Volunteer Network fund is to mobilise a network of people in different services to go out into the community and spread the work and engage with people to discuss the misuse and overuse of antibiotics and their resistance.

Annual Lecture fund represents monies received from Pfizer towards the costs of the 2024 annual lecture.

The transfers in 2022 represent the money spent in ANTRUK Enterprises Ltd on these projects. Also, in 2022 there was a transfer from the Big Give 2020 Programmes fund to Antibiotic Resistance Breakers, Patient Support, Small Research Grants and Reducing Antibiotic Prescribing in line with the funding request.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2023

9. UNRESTRICTED FUNDS

	At 1.1.23 £	Income £	Expenditure £	Transfer £	Tax £	At 31.12.23 £
General unrestricted funds	30,237	268,725	(242,293)	(221)	-	56,448
Non-charitable trading funds	-	-	(221)	221	-	-
	<u>30,237</u>	<u>268,725</u>	<u>(242,514)</u>	<u>-</u>	<u>-</u>	<u>56,448</u>
	<u><u>30,237</u></u>	<u><u>268,725</u></u>	<u><u>(242,514)</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>56,448</u></u>
	2022					
	At 1.1.22 £	Income £	Expenditure £	Transfer £	Tax £	At 31.12.22 £
General unrestricted funds	33,884	201,001	(186,137)	(18,511)	-	30,237
Non-charitable trading funds	1,464	-	(185,441)	183,977	-	-
	<u>35,348</u>	<u>201,001</u>	<u>(371,578)</u>	<u>165,466</u>	<u>-</u>	<u>30,237</u>
	<u><u>35,348</u></u>	<u><u>201,001</u></u>	<u><u>(371,578)</u></u>	<u><u>165,466</u></u>	<u><u>-</u></u>	<u><u>30,237</u></u>

The transfers in both years represents the funds (both restricted for the projects and unrestricted for general expenses) transferred into ANTRUK Enterprises Limited.

10. ANALYSIS OF NET ASSETS BETWEEN FUNDS

Fund balances at 31 December 2023 are represented by:	Unrestricted funds £	Restricted funds £	Total £
GROUP			
Current assets	188,162	434,648	622,810
Creditors: amounts falling due in less than one year	(131,714)	(37,762)	(169,476)
	<u>56,448</u>	<u>396,886</u>	<u>453,334</u>
Total net assets	<u><u>56,448</u></u>	<u><u>396,886</u></u>	<u><u>453,334</u></u>
CHARITY			
Investments	1	-	1
Current assets	188,161	434,648	622,809
Creditors: amounts falling due in less than one year	(131,714)	(37,762)	(169,476)
	<u>56,448</u>	<u>396,886</u>	<u>453,334</u>
Total net assets	<u><u>56,448</u></u>	<u><u>396,886</u></u>	<u><u>453,334</u></u>

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2023

10. ANALYSIS OF NET ASSETS BETWEEN FUNDS (Continued)

Fund balances at 31 December 2022 are represented by:	Unrestricted funds £	Restricted funds £	Total £
GROUP			
Current assets	53,085	410,842	463,927
Creditors: amounts falling due in less than one year	(22,848)	-	(22,848)
Total net assets	30,237	410,842	441,079
CHARITY			
Investments	1	-	1
Current assets	52,535	410,842	463,377
Creditors: amounts falling due in less than one year	(22,299)	-	(22,299)
Total net assets	30,237	410,842	441,079

11. TRUSTEES' REMUNERATION AND EXPENSES

No remuneration was paid or payable directly or indirectly out of the funds of the charity for the period to any trustee or to any person or persons known to be connected with any of them for acting as a trustee.

No trustees were reimbursed expenses (2022: no trustees).

12. RELATED PARTY TRANSACTIONS

In 2022, Garner Consulting Services received £18,965 for consultancy services and received £18,965 for research project management costs from ANTRUK Enterprises Ltd. Professor C Garner (Chief Executive of Antibiotic Research UK until 31 July 2022) and his wife are the partners in Garner Consulting Services.

Telling Data Limited received £27,500 (2022: £12,513) for consultancy services and received £27,500 (2022: £11,458) for research project management costs. The total cost to the group was £55,000 (2022: £23,971). This doesn't included any reimbursed expenses for related items needed to carry out the consultancy this totalled £4,570. Jonathan Pearce (Chief Executive of Antibiotic Research UK from 1 August 2022) is the sole director of Telling Data Limited. Of this amount £5,661 (2022: £4,583) was owed to Telling Data Limited at the year end.

In 2022 before J A Farmer (partner of Azets) resigned, Azets received £1,850 for accounting services.

The aggregated donations made by the trustees were £150 (2022: £380).

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2023

13. GRANT COMMITMENTS

Grant expenditure (charitable activities) committed at 31 December 2023 was as follows:

	Unrestricted funds £	Restricted funds £	Total £
At 1 January 2023	-	284,587	284,587
Commitments paid out	-	(95,554)	(95,554)
Additional commitments	-	-	-
At 31 December 2023	-	189,033	189,033

Grant income committed at 31 December 2023 was £nil within 1 year (2022: £60,000).

Accounts

**ANTIBIOTICS RESEARCH UK -
DEVELOPING NEW ANTIBIOTICS**

UNAUDITED ACCOUNTS

FOR THE YEAR ENDED

31 DECEMBER 2022

Charity number: 1157884

ANTIBIOTICS RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

I N D E X	P A G E
REFERENCE AND ADMINSTRATIVE INFORMATION	1
REPORT OF THE BOARD OF TRUSTEES	3
INDEPENDENT EXAMINER'S REPORT	12
STATEMENT OF FINANCIAL ACTIVITIES	13
BALANCE SHEETS	15
NOTES TO THE ACCOUNTS	16

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REFERENCE AND ADMINISTRATIVE INFORMATION

Charity Name	Antibiotic Research UK – Developing New Antibiotics
Charity Number	1157884
Principal address	Genesis 5 Church Lane Heslington York YO10 5DQ

TRUSTEES

The trustees of the charity are:

Mr S Dukes *	Chair
Mr N Stalbow	(Resigned 16 February 2023)
Mr J A Farmer	Treasurer (resigned 11 April 2022)
Professor C Bond	
Professor C Dowson	
Ms E Lyon*	(Resigned 14 February 2023)
Ms Cathy Tralau-Stewart	(Appointed 20 October 2022)
Mr Phil Robinson *	Chair, Finance Committee (Appointed 20 October 2022)
Ms Carla Brown	(Appointed 20 October 2022, resigned 17 May 2023)
Ms Fiona Russell *	(Appointed 20 October 2022)
Ms Rosemary Howell	(Appointed 20 October 2022)

*Also, member/observer of the Finance Committee

Science Committee

Professor Chris Dowson	Interim Chair
Dr Mike Allen	
Dr Lloyd Czaplewski	
Dr Tina Joshi	
Professor Mark Moloney	(Resigned/end of term of tenure 6 September 2022)
Professor David Roper	(Resigned/end of term of tenure 6 September 2022)
Professor Chris Schofield	
Dr Joe Standing	
Dr Mark Sutton	
Dr David Wareham	
Dr Alan Houston	(Resigned 18 October 2022)
Arlene Brailey	(Appointed 8 February 2022, resigned 31 January 2023)
Dr Chris Longshaw	

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REFERENCE AND ADMINISTRATIVE INFORMATION (Continued)

Public Education and Patient Support Committee

Professor Christine Bond	Chair
James Amos	
Carolyn Childs	
Professor Angharad Davies	(Appointed 26 May 2022)
Dr Ryan Hamilton	
Rebecca Harmston	
Dr Roger Harrison	
Dr Charles Mitchell	
Dr Alison Staples	
Dr Wendy Thompson	(Resigned 16 November 2022)
Dr Neil Todd	
Dr Oliver Van Hecke	

Founding chairman

Mr A Burgess

Chief Executive

Professor R C Garner	(Until 31 July 2022)
Jonathan Pearce	(Appointed 1 August 2022)

Patron

The Most Revd & Rt Hon the Lord Archbishop of York, S Cottrell

ADVISORS

Principal Bankers

Lloyds Bank PLC
2 Pavement
York
YO1 9UP

Independent Examiner

Mr N Clemit ACA, FCCA
JWPCreers LLP
Chartered Accountants
Genesis 5
Church Lane
Heslington
York
YO10 5DQ

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

The trustees present their report and the financial statements of the charity for the year ended 31 December 2022. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) “Accounting and Reporting by Charities” in preparing the annual report and financial statements of the charity.

The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity’s governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published in October 2019.

WHO WE ARE AND WHAT WE DO

Antibiotic Research UK is a national organisation founded in 2014 which raises funds to support antibiotic research, provide information and support to patients and families affected by antimicrobial resistance, raise awareness about its work among the public and professionals, and influence and campaign for better national and international approaches to tackle antimicrobial resistance.

Antibiotic resistance, that is when infectious bacteria become resistant to antibiotic treatment, is on the rise globally. An article published in The Lancet in 2022 estimated that, in 2019, 1.27 million people died globally directly from an antibiotic resistant infection (Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al, Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis, The Lancet, 2022; 399 (10325):629-5), a figure higher than people dying from HIV or malaria. This figure is alarming and whilst the highest number of deaths were in lower and middle income countries, COVID has shown us how quickly an infectious agent can spread around the globe.

Vision

A world free from deaths caused by drug-resistant infections.

Mission

To tackle the global threat of drug-resistant infections by:

- Driving forward innovative solutions to antibiotic resistance
- Improving the lives of people affected by drug-resistant infections
- Raising awareness of the impact of drug-resistant infections

Purpose

- To raise funds to support antibiotic research in the UK’s universities, institutes and organisations
- To campaign, lobby and influence the public agenda for combating antimicrobial resistance
- To provide educational materials about antibiotic resistance to the public and professionals
- To develop a patient support and information network

Values

- We support world-class, peer-reviewed research focussed on bringing new antibiotic therapies to patients in a transparent and open way
- We work to the highest ethical standards and are fully accountable to our stakeholders through open access to all we do
- We have put in place all the necessary governance procedures to comply with the necessary UK regulations and recommendations

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

STRUCTURE, GOVERNANCE AND MANAGEMENT

Constitution and trustee recruitment and appointment

Antibiotic Research UK was registered as a charitable incorporated organisation (CIO), with members, on 16 July 2014 and is governed by its constitution, which can be found on the Charity Commission website. Antibiotic Research UK has a wholly owned trading subsidiary, ANTRUK Enterprises Ltd, which is registered at Companies House (company registration no 10396024).

The work, management, finances and strategy of the charity are overseen by a board of trustees. The trustees who held office during the financial year and at the date of the report are set out on page 1.

The constitution requires there to be a minimum of three trustees and a maximum of twelve trustees in office at any one time. Trustees retire from office after a full term of three years, at the following annual general meeting. A trustee can seek re-election for a further term of office but not a third term without an interval of a year. Trustees can only be formally appointed as a trustee at an annual general meeting although a person can attend meetings as an observer prior to this point.

Purpose

The charity's purposes are set out in its constitution, as follows:

“... to protect and promote the health of the public, in particular by sponsoring research into the diagnosis, treatment and cure of antibiotic-resistant bacterial infectious diseases, ensuring responsible and sustainable development and deployment of the findings of such research, and raising awareness through public-facing activities and the promotion of networks to share experience of such matters.”

Public benefit

The organisation's work delivers public benefit by funding and developing research to address the issue of antibiotic and antimicrobial resistance, which already claim thousands of lives each year nationally and internationally. The number of deaths will continue to increase, unless new antibiotics are discovered and brought to market, and that the use of new and existing antibiotics is better managed and stewarded so as to prolong their use and increase their efficacy.

The organisation also provides invaluable support and assistance to those directly affected by antimicrobial resistance, as well as to the healthcare practitioners working with them. Reliable, evidence-based information and peer support helps them navigate their conditions and improve their longer term outcomes.

As part of our business planning processes, we review our aims and objectives each year, which includes looking at what we have achieved previously, and how our activities have benefited those groups of people we are set up to help. We have referred to the Charity Commission's guidance on public benefit when reviewing our aims and objectives, and in planning our work for the future.

Board and management operations and structure

Board of trustees

The board of trustees meets at least four times a year to review the organisation's work, finances and services, and to agree the strategic goals for the charity. The chief executive officer attends all meetings. The board is also establishing a process to review its own operation, effectiveness and governance.

A finance committee, chaired by the treasurer and comprising at least two other trustees, meets quarterly to monitor and scrutinise the charity's financial strategy and operations, and makes recommendations to the full board of trustees.

REPORT OF THE BOARD OF TRUSTEES

Board and management operations and structure (continued)

The board also operates two other committees, as follows:

Science Committee

The Science Committee is responsible for commissioning and monitoring the charity's scientific research programmes. The Science Committee consists of a number of experienced antimicrobial scientists and clinicians, chaired by Chris Dowson. Full membership details can be found on page 1.

Public Engagement and Patient Support Committee

The Public Engagement and Patient Support Committee (PEPS) is focused on increasing awareness about the importance of tackling drug-resistance amongst professionals and the public. The Committee consists of a range of individuals including clinicians, AMR scientists, public health experts, education professionals and individuals to provide a patient perspective. The committee is chaired by Christine Bond and full membership details can be found on page 2.

Recruitment and appointment of new trustees

An annual review of the recruitment needs of the board of trustees is carried out under the leadership of the chair, including an audit of the current knowledge, experience, skills and abilities, and how they will be affected by any trustee departures in the future. Any trustee vacancies are advertised nationally, and via relevant professional and organisational networks, including the charity's own supporter base, depending upon the expertise and specialisms required. Applicants are shortlisted against the criteria in the person specification for the role of trustee, including any specific qualities highlighted during the above audit. Shortlisted applicants are invited for interview by at least two trustees, one of whom will be the chair. Shortlisted applicants are only appointed where they have the necessary skills and qualities to contribute effectively to the charity's governance and development.

All new trustees receive thorough induction and training, which includes information about the organisation's constitution, accounts, financial reports and minutes of previous trustees' meetings.

Management and organisation

Day-to-day operation of the charity, and strategy implementation, is delegated to the chief executive officer, who is supported by a small team of staff, working in the fields of grant and charity administration, patient support, media, press and PR management, fundraising and financial management.

Risk assessment and management

The organisation has adopted a risk management policy which lists the potential risks to the charity, with an indication of the level of risk.

The main areas of identified risk are in relation to:

- Regulatory and compliance risks arising from the organisation's research, patient support and fundraising work
- Lack of investment in ICT hardware, software and systems, including IT security which impact on business efficiency, business opportunities and business continuity
- Adequate finances and fundraising, due to the external economic situation, changes in funding trends and priorities, and the need to manage committed research expenditure, alongside general organisational resources.
- Operational risks due to the organisation's reliance on a small number of individuals.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

Risk assessment and management (continued)

To address these risks, effective management measures and controls have been put in place by the trustees, including:

- The establishment, review and monitoring of a strong governance framework of organisational policies, standard operating procedures (SOPs) and terms of reference that govern the organisation's work, particularly in the fields of research, patient support, information development and fundraising. A governance committee was established in 2022 to oversee this area of the organisation's work. The charity is registered with the Association of Medical Research Charities (which carries out an online audit every five years) and the Fundraising Regulator.
- Ensuring trustees, committee members and staff have solid experience and expertise in their fields
- An organisational review by an external consultant at the end of 2022/early 2023, which provided an audit of the existing ICT hardware, software and systems, with a set of recommendations for the future, which are being implemented during 2023
- Strong financial oversight from the Finance Committee and Board of Trustees, including maintaining a strong reserves policy and not committing to project expenditure or research commitments until the funds have been secured and banked
- Using consultant employment contracts, supplier contracts and legal agreements to secure relevant expertise and advice, as well as providing for staffing shortfalls, while also reviewing the organisation's staffing model and structure
- Maintaining third-party liability and indemnity insurance

ACHIEVEMENTS AND PERFORMANCE

Although the impact of the Covid pandemic began to lift in 2022, challenges remained across the sector and country's health services as the recovery began. Early in the year we were pleased to be part of the launch of the Infection Management Coalition's White Paper, which set out a broad policy analysis and set of recommendations for the UK on how to tackle infection prevention and control, antibiotic stewardship and the rise of antimicrobial resistance. The Coalition brought together the health/pharmaceutical industry, professional bodies and the third sector with a shared and holistic vision built on the four pillars of: (a) outbreak and pandemic preparedness; (b) infection prevention; (c) rapid recognition, diagnosis and treatment of time-critical viral and bacterial infections; and (d) antimicrobial stewardship. The analysis and recommendations in the White Paper provided the backbone of external and public affairs work during 2022 and into 2023, including Antibiotic Research UK's policy responses and media work on a range of issues, including the role of community pharmacies in antimicrobial stewardship, the then Health Secretary, Thérèse Coffey's misplaced comments on antibiotic usage, and the strep A outbreak towards the end of the year. During the year the Coalition met with members of parliament and engagement work has continued into 2023, including roundtable meetings and representation at external events.

Our research programme continued its work, with the small research grants from 2021 being supplemented with a new project award for the PHASEDIN antimicrobial stewardship trial, based at Southampton University, which will focus on trialling an online toolkit for pharmacists as an intervention to improve antibiotic prescribing for a range of common infections.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

Patient Support

Throughout 2022, our Patient Support Service remained focused on supporting individuals (and their families) in resolving unanswered questions about infection and antibiotic resistance. The number of new enquiries dropped dramatically in 2022 to 272 (compared to 908 in 2021), a direct consequence of the ending of the pandemic, which had previously accounted for a high increase in the number of vaccine-related enquiries. Despite this, the service continued to provide vital support to those affected by resistant infections and we were able to start testing online support groups alongside our traditional phone and email enquiry services, while also updating and expanding the range of healthcare information we have available online or for use in healthcare settings. Our popular ASK Antibiotic Research UK service continued to answer online or via social media frequently asked questions about infections and their management, receiving 212,000 views in 2022, compared to 123,000 in the previous year, thus representing an overall growth of the support we provided compared to pre-pandemic years.

We also succeeded with our patient support outreach, engagement and advocacy work during 2022, working with both NICE and the Scottish Health Technology Group on health technology appraisals and a bacteriophage review, respectively. We also developed a constructive partnership with Well Pharmacy during the year, where we were pleased to provide continuing professional development training to the chain's community pharmacy staff. Furthermore, we made inroads into collaborations with the NHS, including joining the NHS Midlands Regional Medicines Optimisation Group, establishing plans to carry out a pilot programme for distributing information to patients with resistant infections, and agreeing to work with the NHS Black Country Integrated Care Boards on its antimicrobial stewardship initiatives. We were also pleased to attend and present at a number of national events, including the major GP Guidelines Live conference, in order to raise awareness of antibiotic resistance and to provide insight on the patient perspective.

Raising awareness

With the end of the pandemic, 2022 saw a reduction in our website traffic and higher number of Covid and vaccine-related visits dropped. Despite this we had over 350,000 users of the website in 2022 and were proud to have continued to develop the content on our website, particularly in relation to patient-related health information.

During the year we succeeded in maintaining good media coverage (see above for some key examples) and were able to secure key articles in both the mainstream and trade press.

Our communications and campaigns were supported by our vibrant social media activity and by the end of 2022, we grew our Facebook following to 1,553 followers, Twitter to 5,241, Instagram to 707 and LinkedIn to 2,475.

Fundraising

2022 was another challenging year for fundraising. Income streams impacted by lockdown proved slow to bounce back (face-to-face community fundraising and sporting events), and the cost-of-living crisis once again focused funders' attention on frontline emergency relief charities – while the general public had less available funds to donate to charity. The need for charities to invest in other income streams to make up shortfalls resulted in increased competition for funding from Trusts and Foundations. Across the sector, small and medium-sized charities found maintaining income difficult.

Notwithstanding, with great resilience and a renewed focus, we managed to grow income to in-excess of pre-pandemic levels. As always, we are enormously grateful to those who donated and volunteered on our behalf. Without their support we would not be able to continue our vital work.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

Fundraising (continued)

Fundraising highlights in 2022 include:

- £63,000 from The National Lottery Reaching Communities to fund our Patient Support Service for 12 months in England
- £18,000 raised through two online individual giving campaigns which were matched funded by BA Better World Community Fund and The Big Give
- Over £200,000 secured to fund our research programme over 1-2 years from a number of generous Trusts and Foundations
- £15,000 from The York Rotary Dragon Boat Race, as one of their beneficiary charities (with £1,500 raised by the staff of Pavers who paddled the Antibiotic Research UK Dragon Boat)
- £10,000 in corporate support for our Annual Lecture
- Over £20,000 raised through events by our York Volunteer Group and their wider network
- £2,000 raised by fundraisers in the community during World Antimicrobial Awareness Week, including universities, hospitals and corporates

FINANCIAL REVIEW

The consolidated gross income for the year was £399,824 (2021: £409,696). The previous year's income figure included donated services of £80,771, however, there were no donated services during 2022, and thus raised funds have increased from £328,925 (2021) to the current figure of £399,824 in 2022.

The consolidated net movement in funds for the year was a surplus of £250 (2021: deficit of £41,069).

Going concern

Management works to an annual budget and has prepared a forecast to the end of December 2023, along with an outline budget and projections for 2024. These are used by management to ensure the organisation has sufficient funds in place to manage working capital in both the short term and longer term and enables the planning of resource allocation, organisational strategy, sustainability, and development.

Management has identified strong fundraising performance as crucial to positive cash flow management, particularly in relation to unrestricted funding. Fundraising plans and activities and future expenditure management have been reviewed, so as to better understand the impact of varying cashflows on the solvency of the organisation. Budgets have been set in line with the parameters in that review and are sufficient to ensure the organisation has adequate funds to meet its cash flow obligations to the end of 2024. Performance during 2021 highlighted the need to improve financial management and reporting processes within the organisation so that they were focused on agreed fundraising priorities and effective and responsive expenditure management. These areas were reviewed and addressed by trustees and the organisation's management during 2022, with a forward plan developed, with a particular focus on building unrestricted reserves during 2023, while ensuring contingency plans are in place to manage any fundraising shortfalls. These measures have started to prove successful in 2023, although ongoing monitoring and review are required to ensure their sustainability and focus. With these measures in place, trustees are confident about the organisation's ability to continue in operation for at least twelve months from the date of the financial statements.

On this basis, together with the unrestricted funding received in the first eight months of 2023, the Board has approved the preparation of the financial statements on the going concern basis.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

Reserves policy

The trustees aim to maintain a minimum of free reserves equal to 3 months' core expenditure (approximately £60,000). Any funds over this sum will be used to fund the charity's objects.

The year-end level of free reserves was £30,237 (2021: £33,884). As noted above, organisational plans have been implemented to grow unrestricted reserves, including building a predictable and reliable funding base from individual and regular giving, as well as with community and corporate support, and through refocusing some of our fundraising priorities on essential expenditure related to our core mission. These are beginning to deliver promising results in 2023.

PLANS FOR FUTURE PERIODS

With a change of chief executive officers during 2022 – the retirement of our founder, Professor Colin Garner, in August, and the arrival of Jonathan Pearce in August (as reported in last year's report and accounts) – we carried out a review of our strategic plan and business priorities towards the end of the year. The Board agreed to retain the three overarching goals we had set out in our original five-year strategy as approved in 2021, however, within those goals we decided to prioritise and focus our work, particularly on the patients with urinary tract infections (UTIs) that account for approximately 60% of our support services. Accordingly, we have set out our new objectives as follows:

Goal 1: Drive forward innovative solutions to drug-resistant infections

Through collaboration, we will advance research by supporting the development of at least one antibiotic-resistance breaker, antibiotic alternative or combination therapy towards clinical use. We will support under-funded areas of antimicrobial (AMR) research and progress the next generation of researchers in the AMR field.

We will do this by:

Short Term (1–3 years)

- Continuing to run the small research grants/career development awards programme, prioritising grants for basic research and/or health sciences projects, particularly focussing on seed funding and early-career projects for innovative therapeutic (small molecule, biological including phage therapy) approaches to UTI infections (ideally oral) and improved routine diagnostics
- Seeking out funding partnerships to build on existing UTI-based research projects, including the investigation of possible antibiotic combination therapies, alternatives to antibiotics, or improved stewardship initiatives
- Seeking out partnerships for AMR projects related to the behavioural, social sciences and/or applied health sciences (eg, a pilot trial in antibiotic stewardship), increasing the scope for collaboration with policymakers and healthcare providers
- Developing and delivering an education and training programme for both healthcare practitioners and patient communities, thus creating and supporting networks in both aspects of our work
- Building an information hub or directory of core resources to supplement our education and training programme
- Run a priority-setting partnership to determine patient-led research priorities in the field of UTIs

Goal 2: Improve the lives of people affected by drug-resistant infections

We aim to improve the lives of patients and their families by acting as a source of trustworthy information. We will work to reach more patients and build the strength of this patient community so that their collective voice can be heard and to ensure that our services best fit their needs.

REPORT OF THE BOARD OF TRUSTEES

PLANS FOR FUTURE PERIODS (continued)

We will do this by:

Short Term (1–3 years):

- Developing the patient support service to increase capacity and resources in response to need, including:
 - Formalising use of and access to telephone and digital support services
 - Creating online peer support networks
 - Establishing clear, effective systems for the evaluation of our support services
 - Providing information and support to meet the needs of a diverse population of service users
 - Establish evaluation systems
- Developing a digital portfolio of patient information that can be accessed through NHS hospitals, GP surgeries, pharmacies and dentists, increasing awareness of the charity and its services
- Develop a network of volunteers and volunteer groups, focused on providing or signposting towards support in local communities, raising awareness and fundraising

Goal 3: Raise awareness about the impact of drug-resistant infections

We will work to raise the profile of the human impact of drug-resistant infections. We will partner with other organisations to run awareness campaigns and lobby government to drive the policy changes needed to reduce the spread of drug-resistant infections.

We will do this by:

Short Term (1–3 years):

- Developing an influencing, lobbying and campaigning programmes to promote a defined list of key policy/practice asks related to speeding up the AMR agenda and holding the government and other AMR stakeholders to account
- Increasing engagement with universities by helping establish undergraduate AMR societies (or coordinate with existing science and health societies); supporting these societies to organise outreach events for both the university and local communities
- Developing an ambassador programme (patient, community fundraising, healthcare professionals and high-profile/celebrity)
- Develop a corporate partnership package

Long Term (4+ years)

- Investigating opportunities to work with similar national organisations, grow globally and become a leading advocate for the patient voice of drug-resistant infections worldwide.

Behind each of these goals and priorities we have identified a set of enablers, milestones and performance indicators, which we have designed to guide our approaches to potential funders and supporters. In order to achieve our goals, we need to reach more people and organisations willing to support us in the fight against antibiotic resistance. Key to building that platform of financial support are:

- Building a reliable and predictable base of fundraising income from individual gifts and regular givers
- Acquisition of new donors/supporters
- Corporate support.

REPORT OF THE BOARD OF TRUSTEES

PLANS FOR FUTURE PERIODS (continued)

It is a challenging task, but an important one. We hope you will join us in tackling one of the most important health issues of modern times.

TRUSTEES' RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS

The trustees are responsible for preparing the Report of the Board of Trustees' and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of income and expenditure of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2019 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees on 6 September 2023 and signed on their behalf by:



Simon Dukes
Signed on 15/09/23 @ 13:36

.....
Mr S Dukes – Chair

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 December 2022 which comprise the statement of financial activities, balance sheet and relevant notes.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the charity's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW and ACCA.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



N P Clemit
Signed on 18/09/23 @ 11:22

Mr N Clemit ACA, FCCA
JWPCreers LLP
Chartered Accountants
Genesis 5
Church Lane
Heslington
York
YO10 5DQ

19 September 2023

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2022

	Notes	2022 Unrestricted funds £	2022 Restricted funds £	2022 Total funds £	2021 Total funds £
INCOME					
Donations and legacies:					
Donations and grants	2	56,044	10,660	66,704	62,900
Donated services	2	-	-	-	80,771
Charitable activities		107,278	186,755	294,033	236,893
Other trading activities:					
Membership fees		3,745	-	3,745	2,174
Fundraising events		33,934	1,408	35,342	26,958
Total income		<u>201,001</u>	<u>198,823</u>	<u>399,824</u>	<u>409,696</u>
EXPENDITURE					
Raising funds					
Fundraising costs	3	80,108	4,645	84,753	98,064
Donated services		-	-	-	18,420
Charitable activities					
Charitable activities	4	291,470	23,351	314,821	267,686
Donated services		-	-	-	62,351
Total expenditure		<u>371,578</u>	<u>27,996</u>	<u>399,574</u>	<u>446,521</u>
Net (expenditure)/ income		(170,577)	170,827	250	(36,825)
Transfer between funds	8,9	165,466	(165,466)	-	-
Corporation tax receivable		-	-	-	(4,244)
Net movement in funds		(5,111)	5,361	250	(41,069)
Fund balance brought forward at 1 January 2022		<u>35,348</u>	<u>405,481</u>	<u>440,829</u>	<u>481,898</u>
Fund balance carried forward at 31 December 2022	8,9	<u>30,237</u>	<u>410,842</u>	<u>441,079</u>	<u>440,829</u>

All income and expenditure derives from continuing activities.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2022

	Notes	2021 Unrestricted funds £	2021 Restricted funds £	2021 Total funds £
INCOME				
Donations and legacies:				
Donations and grants	2	59,721	3,179	62,900
Donated services	2	80,771	-	80,771
Charitable activities		59,186	177,707	236,893
Other trading activities:				
Membership fees		2,174	-	2,174
Fundraising events		26,958	-	26,958
Total income		228,810	180,886	409,696
EXPENDITURE				
Raising funds				
Fundraising costs	3	98,064	-	98,064
Donated services		18,420	-	18,420
Charitable activities				
Charitable activities	4	262,556	5,130	267,686
Donated services		62,351	-	62,351
Total expenditure		441,391	5,130	446,521
Net (expenditure)/ income		(212,581)	175,756	(36,825)
Transfer between funds	8,9	103,642	(103,642)	-
Corporation tax receivable		(4,244)	-	(4,244)
Net movement in funds		(113,183)	72,114	(41,069)
Fund balance brought forward at 1 January 2021		148,531	333,367	481,898
Fund balance carried forward at 31 December 2021	8,9	35,348	405,481	440,829

All income and expenditure derives from continuing activities.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

BALANCE SHEETS AT 31 DECEMBER 2022

	Notes	Consolidated		Charity only	
		2022 £	2021 £	2022 £	2021 £
FIXED ASSETS					
Investments	5	-	-	1	1
CURRENT ASSETS					
Debtors and prepayments	6	561	4,105	561	1,711
Cash at bank and in hand		463,366	458,794	462,816	458,628
		463,927	462,899	463,377	460,339
LIABILITIES: Amounts falling due within one year	7	(22,848)	(22,070)	(22,299)	(20,975)
NET CURRENT ASSETS		441,079	440,829	441,078	439,364
NET ASSETS		441,079	440,829	441,079	439,365
THE FUNDS OF THE CHARITY					
Unrestricted funds	9	30,237	35,348	30,237	33,884
Restricted funds	8	410,842	405,481	410,842	405,481
TOTAL CHARITY FUNDS		441,079	440,829	441,079	439,365

Approved by the trustees on 6 September 2023 and signed on their behalf by:



Simon Dukes
Signed on 15/09/23 @ 13:36

.....
Mr S Dukes - Chair

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2022

1. ACCOUNTING POLICIES

Basis of accounting

Antibiotic Research UK – Developing New Antibiotics is a charitable incorporated organisation in England. The address of the registered office is given in the charity information within the trustees' report of these financial statements.

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011, and UK Generally Accepted Accounting Practice.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are prepared in sterling which is the functional currency of the charity.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

Group financial statements

These financial statements consolidate the results of the charity and its wholly owned subsidiary ANTRUK Enterprises Limited on a line by line basis.

The gross income of the charity for the year was £399,824 and the result of the charity for the year was net surplus of £1,714.

Going Concern

The charity's financial statements are prepared on a going concern basis on the grounds that current and future sources of funding or support will be more than adequate for the charity's needs. The trustees have considered a period of twelve months from the date of approval of the financial statements and believe that no further disclosures relating to the charity's ability to continue as a going concern need to be made in the financial statements.

Fund accounting

Unrestricted funds are funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

Restricted funds are donations which the donor has specified are to be solely used for particular areas of the charity's work or for specific projects being undertaken by the charity.

Income

All income is included in the statement of financial activities when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donated services are accounted for at a reasonable estimate of their value to the charity and are included in the statement of financial activities as income when receivable.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2022

1. ACCOUNTING POLICIES (Continued)

Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Raising funds relates to costs incurred directly to generate donations. Charitable expenditure comprises those costs incurred by the charity in pursuit of its charitable object. Grants payable are charged in the year when the offer is conveyed to the recipient.

Tangible fixed assets and depreciation

Individual fixed assets costing £500 or more are capitalised at cost. Currently Antibiotic Research UK has no tangible fixed assets.

Debtors

Trade and other debtors are recognised at the settlement amount due. Prepayments are valued at the amount net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2. DONATIONS AND GRANTS

	2022 Unrestricted Funds £	2022 Restricted Funds £	2022 Total Funds £	2021 Unrestricted Funds £	2021 Restricted Funds £	2021 Total Funds £
Donations	12,992	-	12,992	25,720	-	25,720
Gift Aid	13,316	-	13,316	12,473	-	12,473
Online giving	29,736	10,660	40,396	21,528	3,179	24,707
	<u>56,044</u>	<u>10,660</u>	<u>66,704</u>	<u>59,721</u>	<u>3,179</u>	<u>62,900</u>
Donated services	-	-	-	80,771	-	80,771
	<u>56,044</u>	<u>10,660</u>	<u>66,704</u>	<u>140,492</u>	<u>3,179</u>	<u>143,671</u>

Included in donations in the prior year were proceeds of £6,933 gained from the dispersal of donated shares received during the year.

Donated services in the prior year were legal services provided pro bono by Ashurst LLP, London and professional services by Costello Medical, Bow House Digital and ASF Alison Staples Fundraiser.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2022

3. RAISING FUNDS EXPENDITURE

	2022 Unrestricted Funds £	2022 Restricted Funds £	2022 Total Funds £	2021 Unrestricted Funds £	2021 Restricted Funds £	2021 Total Funds £
Fundraiser fees	77,810	4,615	82,425	109,494	-	109,494
Fundraising expenses	2,298	30	2,328	6,990	-	6,990
	<u>80,108</u>	<u>4,645</u>	<u>84,753</u>	<u>116,484</u>	<u>-</u>	<u>116,484</u>

Fundraising fees includes £nil (2021: £18,420) of donated services.

4. CHARITABLE ACTIVITIES

	2022 Unrestricted Funds £	2022 Restricted Funds £	2022 Total Funds £	2021 Unrestricted Funds £	2021 Restricted Funds £	2021 Total Funds £
Trading subsidiary	5 185,441	-	185,441	120,359	-	120,359
Patient support costs	-	5,364	5,364	-	3,519	3,519
Legal and professional fees	54,754	4,921	59,675	143,192	1,000	144,192
Consultancy fees	26,935	4,546	31,481	31,171	611	31,782
Accountancy	9,146	-	9,146	9,552	-	9,552
Printing, postage and stationery	375	586	961	1,522	-	1,522
Website and IT	6,642	90	6,732	12,926	-	12,926
Phone and internet	198	-	198	102	-	102
Computer and software	4,008	-	4,008	435	-	435
Insurance	407	-	407	578	-	578
Travel and subsistence	1,386	224	1,610	189	-	189
Bank and CAF charges	1,293	-	1,293	1,221	-	1,221
Recruitment costs	885	-	885	969	-	969
Annual lecture costs	-	4,494	4,494	2,691	-	2,691
Student engagement sponsorship work	-	3,126	3,126	-	-	-
	<u>291,470</u>	<u>23,351</u>	<u>314,821</u>	<u>324,907</u>	<u>5,130</u>	<u>330,037</u>

Legal and professional fees include £nil (2021: £62,351) of donated services.

Accountancy fees includes payments to the independent examiner of £2,826 (2021: £2,712) for the independent examination and £960 (2021: £1,260) for other accountancy services.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2022

5. TRADING SUBSIDIARY

The wholly owned trading subsidiary, ANTRUK Enterprises Ltd (company number: 10396024), which was incorporated in England and Wales on 27 September 2016, provides funding to research projects concerning antibiotics. The charity owns the entire issued share capital of 1 ordinary share of £1. A summary of the trading results is shown below. Monies are granted from the charity to the trading subsidiary to fund research projects.

The activities of the subsidiary are being transferred to the charity and therefore are discontinuing within the subsidiary but continuing within the group.

Summary profit and loss account

	2022 £	2021 £
Research costs and administration expenses	(185,441)	(120,359)
Income from group undertakings	183,977	120,361
Corporation tax (payable)/ repayable	-	(4,244)
Retained in subsidiary	(1,464)	(4,242)
The assets and liabilities of the subsidiary were:		
Current assets	5,109	4,654
Creditors: amounts falling due within one year	(5,108)	(3,189)
Total net assets	1	1,465
Aggregate share capital and reserves	1	1,465

Included within research costs are grants made to 6 institutions for £101,437. There were no grants made to individuals.

6. DEBTORS

	2022 Group £	2021 Group £	2022 Charity £	2021 Charity £
Prepayments and accrued income	561	1,711	561	1,711
VAT	-	2,394	-	-
	561	4,105	561	1,711

7. CREDITORS DUE WITHIN ONE YEAR

	2022 Group £	2021 Group £	2022 Charity £	2021 Charity £
Accounts payable	6,428	-	6,428	-
Accruals	16,420	22,070	11,312	18,881
Amounts owed to group undertakings	-	-	4,559	2,094
	22,848	22,070	22,299	20,975

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2022

8. RESTRICTED FUNDS

	2022				
	At 1.1.22 £	Income £	Expenditure £	Transfer £	At 31.12.22 £
Antibiotic Resistance Breakers	68,879	-	-	5,082	73,961
Patient Support	13,097	15,620	(6,269)	(13,816)	8,632
Combined Research 2019	54,419	-	-	(54,419)	-
Test Discs	54,090	-	-	-	54,090
Combined Research 2019 including Test Discs	62,824	-	-	(18,884)	43,940
Small Research Grants	25,000	19,710	-	3,662	48,372
Mutate Trial	8,457	26,200	-	-	34,657
Big Give 2020 programmes	18,075	-	-	(18,075)	-
Combined Research 2020 including mutate trial & non-antibiotic alternatives	19,049	-	-	(19,049)	-
Combined Research 2021	27,795	-	-	(27,795)	-
TNL England	9,135	57,582	(9,106)	(16,746)	40,865
TNL Wales	4,101	-	-	-	4,101
TNL Northern Ireland	2,443	-	-	-	2,443
PhD student support	27,500	27,500	(325)	(2,500)	52,175
Reducing Antibiotic Prescribing Student Programme	10,617	38,461	(130)	(1,216)	47,732
Annual Lecture	-	3,750	(3,126)	(750)	(126)
	-	10,000	(9,040)	(960)	-
	<u>405,481</u>	<u>198,823</u>	<u>(27,996)</u>	<u>(165,466)</u>	<u>410,842</u>
	2021				
	At 1.1.21 £	Income £	Expenditure £	Transfer £	At 31.12.21 £
Antibiotic Resistance Breakers	68,879	-	-	-	68,879
Patient Support	-	19,387	(4,519)	(1,771)	13,097
Combined Research 2019	55,030	-	(611)	-	54,419
Test Discs	64,269	-	-	(10,179)	54,090
Combined Research 2019 including Test Discs	62,824	-	-	-	62,824
Small Research Grants	25,000	-	-	-	25,000
Mutate Trial	-	48,812	-	(40,355)	8,457
Big Give 2020 programmes	18,075	-	-	-	18,075
Combined Research 2020 including mutate trial & non-antibiotic alternatives	19,049	-	-	-	19,049
Combined Research 2021	-	51,727	-	(23,932)	27,795
TNL Scotland	2,017	5,976	-	(7,993)	-
TNL England	18,224	8,819	-	(17,908)	9,135
TNL Wales	-	4,593	-	(492)	4,101
TNL Northern Ireland	-	2,736	-	(293)	2,443
PhD student support	-	27,500	-	-	27,500
Reducing Antibiotic Prescribing	-	11,336	-	(719)	10,617
	<u>333,367</u>	<u>180,886</u>	<u>(5,130)</u>	<u>(103,642)</u>	<u>405,481</u>

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2022

8. RESTRICTED FUNDS (Continued)

Antibiotic Resistance Breakers (ARB) fund represents monies donated to fund the research into ARBs, this incorporates the Holbeck Charitable Trust funding as it was for the same cause.

Patient Support fund represents monies donated to fund a patient support officer whose role will be to develop a portfolio of patient support resources for people affected by antimicrobial resistance.

Combined Research 2019 fund represents monies donated towards a specific application for funds from Antibiotics Research that identified expenditure across three programmes. Research into new antibiotic therapies, research into non-antibiotic alternatives (Diamond), and a small research grants scheme.

Test Discs funds represents monies donated towards the next stage of research. The manufacture and circulation to partners of a test disk sensitivity kit for further testing.

Combined Research 2019 Including Test Discs fund represents monies donated towards both of the above two funds.

Small Research Grants fund represents monies donated towards the small research grants programmes.

Mutate Trial fund represents monies donated for the next phase of the MUTATE research programme which is working with hospital microbiology labs in a round robin evaluation of cefepime / sulbactam test discs.

Big Give 2020 Combined Projects fund represents monies donated through the online platform Big Give. Antibiotic Research identified the expenditure would cover patient support, original antibiotic resistance breakers and the small grants programmes.

Combined Research 2020 Including Mutate Trial & Non-Antibiotic Alternatives fund represents monies donated to the above 2020 combination and includes expenditure on Non-Antibiotic alternatives.

Combined Research 2021 fund represents monies donated towards small research grants and early careers development awards.

TNL Scotland (2021 only) fund represents a National Lottery Award, monies donated are to be used to give Scottish Support Network for People Affected by antibiotic resistant infections in Aberdeen.

TNL England fund represents a National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in England.

TNL Wales fund represents a National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in Wales.

TNL Northern Ireland fund represents a National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in Northern Ireland.

PhD student support fund represents monies donated by the Troutdale Trust to support a PhD student.

Reducing Antibiotic Prescribing through triaging using Point of Care testing fund represents monies donated for the Study Protocol Development and planning for the scaled up roll out of the study.

Student Programme represents monies donated to further engagement with university students across the UK through the development of a Student AMR Society Scheme and activities such as 'The Great University Science Quiz' (online).

Annual Lecture fund represents monies received from Pfizer towards the costs of the 2022 annual lecture.

The transfers represent the money spent in ANTRUK Enterprises Ltd on these projects. Also in 2022 there was a transfer from the Big Give 2020 Programmes fund to Antibiotic Resistance Breakers, Patient Support, Small Research Grants and Reducing Antibiotic Prescribing in line with the funding request.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2022

9. UNRESTRICTED FUNDS

	At 1.1.22 £	Income £	Expenditure £	Transfer £	Tax £	At 31.12.22 £
General unrestricted funds	33,884	201,001	(186,137)	(18,511)	-	30,237
Non-charitable trading funds	1,464	-	(185,441)	183,977	-	-
	<u>35,348</u>	<u>201,001</u>	<u>(371,578)</u>	<u>165,466</u>	<u>-</u>	<u>30,237</u>
2021						
	At 1.1.21 £	Income £	Expenditure £	Transfer £	Tax £	At 31.12.21 £
General unrestricted funds	142,825	228,810	(321,033)	(16,718)	-	33,884
Non-charitable trading funds	5,706	-	(120,358)	120,360	(4,244)	1,464
	<u>148,531</u>	<u>228,810</u>	<u>(441,391)</u>	<u>103,642</u>	<u>(4,244)</u>	<u>35,348</u>

The transfers in both years represents the funds (both restricted for the projects and unrestricted for general expenses) transferred into ANTRUK Enterprises Limited.

10. ANALYSIS OF NET ASSETS BETWEEN FUNDS

Fund balances at 31 December 2022 are represented by:	Unrestricted funds £	Restricted funds £	Total £
GROUP			
Current assets	53,085	410,842	463,927
Creditors: amounts falling due in less than one year	(22,848)	-	(22,848)
Total net assets	<u>30,237</u>	<u>410,842</u>	<u>441,079</u>
CHARITY			
Investments	1	-	1
Current assets	52,535	410,842	463,377
Creditors: amounts falling due in less than one year	(22,299)	-	(22,299)
Total net assets	<u>30,237</u>	<u>410,842</u>	<u>441,079</u>

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2022

10. ANALYSIS OF NET ASSETS BETWEEN FUNDS (Continued)

Fund balances at 31 December 2021 are represented by:	Unrestricted funds £	Restricted funds £	Total £
GROUP			
Current assets	57,418	405,481	462,899
Creditors: amounts falling due in less than one year	(22,070)	-	(22,070)
Total net assets	35,348	405,481	440,829
CHARITY			
Investments	1	-	1
Current assets	54,858	405,481	460,339
Creditors: amounts falling due in less than one year	(20,975)	-	(20,975)
Total net assets	33,884	405,481	439,365

11. TRUSTEES' REMUNERATION AND EXPENSES

No remuneration was paid or payable directly or indirectly out of the funds of the charity for the period to any trustee or to any person or persons known to be connected with any of them for acting as a trustee.

No trustees were reimbursed expenses (2021: no trustees).

12. RELATED PARTY TRANSACTIONS

Garner Consulting Services received £18,965 (2021: £31,782) for consultancy services and received £18,965 (2021: £31,782) for research project management costs from ANTRUK Enterprises Ltd. As ANTRUK Enterprises Ltd was VAT registered for part of the year the net cost was £15,804. The total cost to the group was £34,798 (2021: £58,267). Professor C Garner (Chief Executive of Antibiotic Research UK until 31 July 2022) and his wife are the partners in Garner Consulting Services. Of this amount £nil was owed to Garner Consulting Services at the year end (2021: £5,419).

Telling Data Limited received £12,513 (2021: £nil) for consultancy services and received £11,458 (2021: £nil) for research project management costs from ANTRUK Enterprises Ltd. The total cost to the group was £23,971 (2021: £nil). Jonathan Pearce (Chief Executive of Antibiotic Research UK from 1 August 2022) is the sole director of Telling Data Limited. Of this amount £4,583 (2021: £nil) was owed to Telling Data Limited at the year end.

Azets of which J A Farmer is a partner received £5,833 (2021: £7,180) for accounting services.

Ashurst LLP, of which N Stalbow is a partner, have provided pro bono services to the value of £nil (2021: £1,536).

The aggregated donations made by the trustees were £380 (2021: £1,025).

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS
NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2022

13. GRANT COMMITMENTS

Grant expenditure (charitable activities) committed at 31 December 2022 was as follows:

	Unrestricted funds £	Restricted funds £	Total £
At 1 January 2022	-	108,795	108,795
Commitments paid out	-	(56,523)	(56,523)
Additional commitments	-	232,315	232,315
At 31 December 2022	-	284,587	284,587

Grant income committed at 31 December 2022 was £60,000 within 1 year (2021: £30,000) and £nil within 2 years (2021: £30,000).

14. FUNDS HELD ON BEHALF OF OTHERS

	Bark de Triumph £	Dragonboat Race £
Funds held at 1 January 2022	-	-
Income received as agent	13,092	600
Expenditure paid as agent	(13,092)	(600)
Funds held at 31 December 2022	-	-

Antibiotic Research UK acted as an agent for funds relating to fundraising events. They had no control over the transactions that occurred. The transactions were recorded within their accounting software such that the funds could be identified.

Accounts

**ANTIBIOTICS RESEARCH UK -
DEVELOPING NEW ANTIBIOTICS**

UNAUDITED ACCOUNTS

FOR THE YEAR ENDED

31 DECEMBER 2021

Charity number: 1157884

ANTIBIOTICS RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

I N D E X	P A G E
REFERENCE AND ADMINSTRATIVE INFORMATION	1
CHAIR’S INTRODUCTION	3
REPORT OF THE BOARD OF TRUSTEES	4
INDEPENDENT EXAMINER’S REPORT	12
STATEMENT OF FINANCIAL ACTIVITIES	13
BALANCE SHEETS	14
NOTES TO THE ACCOUNTS	15

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REFERENCE AND ADMINISTRATIVE INFORMATION

Charity Name	Antibiotic Research UK – Developing New Antibiotics
Charity Number	1157884
Principal address	Genesis 5 Church Lane Heslington York YO10 5DQ

TRUSTEES

The trustees of the charity are:

Mr S Dukes *	Chair (from 21 October 2021)
Mr N Stalbow	Interim chair (until 1 January 2021)
Mr J A Farmer	Treasurer (resigned 11 April 2022)
Professor C Bond	
Professor C Dowson	
Ms E Lyon *	
Ms Y Thakurdas	(Resigned 1 January 2021)

Observers:

Ms Cathy Tralau-Stewart	(Appointed 7 February 2022)
Mr Phil Robinson *	(Appointed 7 February 2022)
Ms Carla Brown	(Appointed 7 February 2022)
Ms Fiona Russell *	(Appointed 7 February 2022)
Ms Rosemary Howell	(Appointed 7 February 2022)

*Also, member/observer of the Finance Committee

Science Committee

Professor Chris Dowson	Interim Chair (from 1 st November 2021)
Dr Lloyd Payne	Chair (appointed 1 st February 2021; resigned 25 October 2021)
Dr Mike Allen	
Dr Lloyd Czaplewski	
Dr Tina Joshi	
Professor Mark Moloney	(Resigned/end of term of tenure 6 September 2022)
Professor David Roper	(Resigned/end of term of tenure 6 September 2022)
Professor Chris Schofield	
Dr Joe Standing	
Dr Mark Sutton	
Dr David Wareham	
Dr Alan Houston	(Appointed 27 May 2021)
Arlene Brailey	(Appointed 8 February 2022)
Dr Chris Longshaw	

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REFERENCE AND ADMINISTRATIVE INFORMATION (Continued)

Public Education and Patient Support Committee

Professor Christine Bond Chair
James Amos
Carolyn Childs
Professor Angharad Davies (Appointed 26 May 2022)
Dr Ryan Hamilton
Rebecca Harmston
Dr Roger Harrison
Dr Charles Mitchell
Dr Alison Staples
Dr Wendy Thompson
Dr Neil Todd
Dr Oliver Van Hecke

Founding chairman

Mr A Burgess

Chief Executive

Professor R C Garner (Until 31 July 2022)
Jonathan Pearce (Appointed 1 August 2022)

Patron

The Most Revd & Rt Hon the Lord Archbishop of York, S Cottrell
(from November 2021)

ADVISORS

Principal Bankers

Lloyds Bank PLC
2 Pavement
York
YO1 9UP

Independent Examiner

Mr N Clemit ACA, FCCA
JWPCreers LLP
Chartered Accountants
Genesis 5
Church Lane
Heslington
York
YO10 5DQ

CHAIR'S INTRODUCTION

Since my appointment as Chair Designate in January 2021 and confirmed at the 2021 Annual General Meeting, I have learned much that I didn't know before I joined the charity about the problem of antimicrobial resistance. As a 'concerned' citizen I am very anxious that common infections requiring antibiotic treatment continue to be treated effectively. I want to also see future generations benefit in the same way as our generation has from these miracle drugs.

Antibiotic Research UK (ANTRUK) is the UK's only publicly funded charity tackling the major health issue of drug-resistant infections. With its broad remit of research, education and patient services, the charity has over the years punched above its weight. It has met Ministers and Parliamentarians, has provided a patient voice particularly to pharmaceutical companies, NESTA, the Longitude Prize and NICE - we have become the go to charity for any information about antibiotic resistance. The growth in traffic to our website during the COVID pandemic has been truly remarkable – at the peak of the pandemic over 187,000 people visited the website each month. Here they could find trusted sources of information, a touchstone for all that the charity is about.

In 2021, after my appointment I set about bringing new faces to the Trustee Board. I am pleased to report that five new trustee designates have been appointed, bringing fresh perspectives and ideas. I look forward to working with them as we move the charity from its start-up phase to a more mature charity.

As a result of our Business Strategy review, I am pleased to report that the trustees took the decision to rebalance the charity's focus and expenditure deciding to focus 60% of its resources on research and 40% on patient services.

Following the retirement of the now Baron Sentamu of Lindisfarne and Masooli from the Archbishopric of York, we were delighted and honoured that his successor, The Most Reverend and Right Honourable Stephen Cottrell the Archbishop of York and Primate of England, has agreed to continue in the role as the charity's Patron. We look forward to welcoming His Grace to future charity events.

We also learned in 2021 of Professor Colin Garner's (our chief executive and the charity's founder) decision to retire at the end of July 2022. It has been a privilege to work alongside Colin and witness his many achievements in setting up and building the organisation that is now Antibiotic Research UK. On behalf of the organisation and the AMR sector as a whole, we are grateful for his inspiration, insight, dedication and persistence. We wish him well in retirement, while also looking forward to welcoming Jonathan Pearce as our new CEO in August 2022.

A charity such as ours is all about people: the people who work and volunteer for us and very importantly our donors. What makes our charity unique is that we are in the privileged position of being able to hear patient stories first-hand about the dreadful impact antibiotic resistant infections can have on lives. The fact that we are also in the position to directly help and support them provides me with a great deal of personal satisfaction. The 'Hidden Pandemic' as we describe the problem of bacterial resistance, is one that needs to come out much more into the open. The continued and amazing work of Antibiotic Research UK will ensure this will happen.



Simon Dukes
Signed on 20/10/22 @ 12:59

Simon Dukes
Chair

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

The trustees present their report and the financial statements of the charity for the year ended 31 December 2021. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) “Accounting and Reporting by Charities” in preparing the annual report and financial statements of the charity.

The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity’s governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published in October 2019.

WHO WE ARE AND WHAT WE DO

Antibiotic Research UK is a national organisation founded in 2014 which raises funds to support antibiotic research, provide information and support to patients and families affected by antimicrobial resistance, raise awareness about its work among the public and professionals, and influence and campaign for better national and international approaches to tackle antimicrobial resistance.

Antibiotic resistance, that is when infectious bacteria become resistant to antibiotic treatment, is on the rise globally. It has been estimated that in 2019, 1.27 million people died globally directly from an antibiotic resistant infection (Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al, *Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis*, The Lancet, 2022; 399 (10325):629-5), a figure higher than people dying from HIV or malaria. This figure is alarming and whilst the highest number of deaths were in lower- and middle-income countries, COVID has shown us how quickly an infectious agent can spread around the globe.

Vision

A world free from deaths caused by drug-resistant infections.

Mission

To tackle the global threat of drug-resistant infections by:

- Driving and enabling innovative and collaborative research to ensure future generations have access to effective treatments.
- Supporting patients and families that are affected by drug-resistant infections.
- Working in partnership with key stakeholders to raise awareness and reduce the spread of drug-resistant infections.

Purpose

- To raise funds to support antibiotic research in the UK’s universities, institutes and organisations
- To campaign, lobby and influence the public agenda for combating antimicrobial resistance
- To provide educational materials about antibiotic resistance to the public and professionals
- To develop a patient support and information network

Values

- We support world-class, peer-reviewed research focussed on bringing new antibiotic therapies to patients in a transparent and open way
- We work to the highest ethical standards and are fully accountable to our stakeholders through open access to all we do
- We have put in place all the necessary governance procedures to comply with the necessary UK regulations and recommendations

REPORT OF THE BOARD OF TRUSTEES

STRUCTURE, GOVERNANCE AND MANAGEMENT

Constitution and trustee recruitment and appointment

Antibiotic Research UK was registered as a charitable incorporated organisation (CIO), with members, on 16 July 2014 and is governed by its constitution, which can be found on the Charity Commission website. Antibiotic Research UK has a wholly owned trading subsidiary, ANTRUK Enterprises Ltd, which is registered at Companies House (company registration no 10396024).

The work, management, finances and strategy of the charity are overseen by a board of trustees. The trustees who held office during the financial year and at the date of the report are set out on page 1.

The constitution requires there to be a minimum of three trustees and a maximum of twelve trustees in office at any one time. Trustees retire from office after a full term of three years, at the following annual general meeting. A trustee can seek re-election for a further term of office but not a third term without an interval of a year. Trustees can only be formally appointed as a trustee at an annual general meeting although a person can attend meetings as an observer prior to this point.

Purpose

The charity's purposes are set out in its constitution, as follows:

“... to protect and promote the health of the public, in particular by sponsoring research into the diagnosis, treatment and cure of antibiotic-resistant bacterial infectious diseases, ensuring responsible and sustainable development and deployment of the findings of such research, and raising awareness through public-facing activities and the promotion of networks to share experience of such matters.”

Public benefit

The organisation's work delivers public benefit by funding and developing research to address the issue of antibiotic and antimicrobial resistance, which already claim thousands of lives each year nationally and internationally. The number of deaths will continue to increase, unless new antibiotics are discovered and brought to market, and that the use of new and existing antibiotics is better managed and stewarded so as to prolong their use and increase their efficacy.

The organisation also provides invaluable support and assistance to those directly affected by antimicrobial resistance, as well as to the healthcare practitioners working with them. Reliable, evidence-based information and peer support helps them navigate their conditions and improve their longer term outcomes.

As part of our business planning processes, we review our aims and objectives each year, which includes looking at what we have achieved previously, and how our activities have benefited those groups of people we are set up to help. We have referred to the Charity Commission's guidance on public benefit when reviewing our aims and objectives, and in planning our work for the future.

Board and management operations and structure

Board of trustees

The board of trustees meets at least four times a year to review the organisation's work, finances and services, and to agree the strategic goals for the charity. The chief executive officer attends all meetings. The board is also establishing a process to review its own operation, effectiveness and governance.

A finance committee, chaired by the treasurer and comprising at least two other trustees, meets quarterly to monitor and scrutinise the charity's financial strategy and operations, and makes recommendations to the full board of trustees.

REPORT OF THE BOARD OF TRUSTEES

Board and management operations and structure (continued)

The board also operates two other committees, as follows:

Science Committee

The Science Committee is responsible for commissioning and monitoring the charity's scientific research programmes. The Science Committee consists of a number of experienced antimicrobial scientists and clinicians, chaired by Chris Dowson. Full membership details can be found on page 1.

Public Engagement and Patient Support Committee

The Public Engagement and Patient Support Committee (PEPS) is focused on increasing awareness about the importance of tackling drug-resistance amongst professionals and the public. The Committee consists of a range of individuals including clinicians, AMR scientists, public health experts, education professionals and individuals to provide a patient perspective. The committee is chaired by Christine Bond and full membership details can be found on page 2.

Recruitment and appointment of new trustees

An annual review of the recruitment needs of the board of trustees is carried out under the leadership of the chair, including an audit of the current knowledge, experience, skills and abilities, and how they will be affected by any trustee departures in the future. Any trustee vacancies are advertised nationally, and via relevant professional and organisational networks, including the charity's own supporter base, depending upon the expertise and specialisms required. Applicants are shortlisted against the criteria in the person specification for the role of trustee, including any specific qualities highlighted during the above audit. Shortlisted applicants are invited for interview by at least two trustees, one of whom will be the chair. Shortlisted applicants are only appointed where they have the necessary skills and qualities to contribute effectively to the charity's governance and development.

All new trustees receive thorough induction and training, which includes information about the organisation's constitution, accounts, financial reports and minutes of previous trustees' meetings.

Management and organisation

Day-to-day operation of the charity, and strategy implementation, is delegated to the chief executive officer, who is supported by a small team of staff, working in the fields of grant administration, patient support, media, press and PR management, fundraising and financial management.

Risk assessment and management

The organisation has adopted a risk management policy which lists the potential risks to the charity, with an indication of the level of risk.

The main areas of identified risk are in relation to:

- Regulatory and compliance risks arising from the organisation's research, patient support and fundraising work.
- The provision of accurate and up-to-date patient information in a complex scientific and medical field.
- Adequate finances and fundraising, due to the external economic situation, changes in funding trends and priorities, and the need to manage committed research expenditure, alongside general organisational resources.
- Operational risks due to the organisation's reliance on a small number of individuals.

REPORT OF THE BOARD OF TRUSTEES

Risk assessment and management (continued)

To address these risks, effective management measures and controls have been put in place by the trustees, including:

- The establishment, review and monitoring of a strong framework of standard operating procedures (SOPs) and terms of reference that govern the organisation's work, particularly in the fields of research, patient support, information development and fundraising. The charity is registered with the Association of Medical Research Charities (which carries out an online audit every five years) and the Fundraising Regulator.
- Ensuring trustees, committee members and staff have solid experience and expertise in their fields.
- Strong financial oversight from the Finance Committee and Board of Trustees, including maintaining a strong reserves policy and not committing to project expenditure or research commitments until the funds have been secured and banked.
- Using consultant employment contracts, supplier contracts and legal agreements to secure relevant expertise and advice, as well as providing for staffing shortfalls.
- Maintaining third-party liability and indemnity insurance.

ACHIEVEMENTS AND PERFORMANCE

With the pandemic continuing in 2021, it remained a challenging time for all charities, with COVID-19 impacting on us in so many ways, internationally, nationally, locally and personally. Working together with Costello Medical, Cambridge, we published a joint review on hospital antibiotic prescribing during the pandemic and found that in general early on in the pandemic, hospital admitted patients were likely to be prescribed antibiotics whether they had a bacterial infection or not (Cherry W, Brown M, Garner C, *A rapid review of the overuse of antibiotics during the COVID-19 pandemic: lessons learned and recommendations for the future*, AMRC Reviews, 2021). Also together with Costello, we analysed primary care antibiotic prescribing in England since 2014 and found that during the COVID pandemic there was a 14% reduction in antibiotic prescribing resulting in our programme, 'Let's keep it down'.

During the year, our Board approved the provision of £200,000 in funding for our Small Research Grants programme, a vital plank of support in sustaining the funding of young university career researchers. In total eight grants were awarded on a competitive basis (see <https://www.antibioticresearch.org.uk/small-research-grants/2021-awards-grants-to-fund-research/> for full details of the awards). In addition, the organisation continued to fund its Antibiotic Resistance Breaker programme out of which has come a combination therapy of cefepime / sulbactam which appears effective in treating some drug-resistant Gram-negative bacterial species.

Patient Support

Throughout 2021, our Patient Support Service remained focused on supporting individuals (and their families) in resolving unanswered questions about infection and antibiotic resistance. The number of new enquiries and contacts we dealt with grew dramatically in 2021, totalling 908, compared to 93 new contacts in 2020, testament to the value of the information and support we provide. With the advent of Covid-19 vaccines early in 2021, the number of enquiries grew significantly, with a large proportion being on Covid-related questions from those taking or wishing to take antibiotics while suffering from Covid or undergoing testing or vaccinations. We became a trusted source of information on these matters, where medical services were often unable to provide answers to patients.

We also introduced a programme of virtual patient support groups, which included an educational element on topics like 'how do bacteria develop resistance to antibiotics', using lay-person and patient-friendly formats and supported by expert speakers in the field of antibiotic resistance. These virtual meetings and our online community group act as lifelines for patients meeting together, reducing that common sense of isolation and frustration. We continue to develop these forms of support in 2022.

We also used our patient support expertise to develop new content for our website, as well as produce leaflets about antibiotic resistance for use in community pharmacies, publish articles and support the ASK Antibiotic Research UK service in which we post answers online or via social media to frequently asked questions about infections and their management (which received 123,000 views in 2021, compared to 7,000 in the previous year).

REPORT OF THE BOARD OF TRUSTEES

Patient Support (continued)

Our team continued to advocate for the patient voice in 2021 by supporting sufferers to share their stories, not just as website content but also by video. Patients described the impact of recurring and resistant infections on their lives and shared this at major conferences to highlight the patient perspective of antibiotic resistance. We also introduced two new Patient Ambassadors, Ronda and Lisa, who shared their experience as part of patient safety initiatives, reaching over 63,000 and 150,000 viewers, respectively.

On top of all this, we were delighted when the unique service provided by the Patient Support Service was recognised by a Bionow Antimicrobial Resistance (AMR) award in February 2021.

Raising awareness

During 2021 we saw our website take on an even more prominent role in our work than previously. We had over 1.2 million page views and 869,000 users (up from 200,000 in 2020). Some of this was driven by the review and update of our content and messaging, as well as by increased and more effective media coverage from our press work and campaigns. Among the extensive media coverage we achieved, we called for:

- clear health guidance to ensure people on antibiotics didn't miss out on Covid-19 vaccines as they became available;
- a change in the way new antibiotic sales are funded so as to avoid another health emergency; and
- a winter campaign to change the way antibiotics are prescribed.

Our communications and campaigns were supported by our vibrant social media activity and by the end of 2021, we grew our Facebook and Twitter followings to 1,500 and 4,700, respectively.

Fundraising

Like many other charities we had a challenging year financially in 2021, with reduced face-to-face fundraising activities. Therefore, we came up with novel online ways of raising funds including a virtual bridge event and the Great University Science Quiz. Some grant-making trusts and foundations that had previously supported us took a break in 2021 citing increasing demands for funding, a refocusing of funding priorities to emergency frontline funding for local communities or to allow a 're-set' after unprecedented giving in the previous year during the height of the pandemic. As a result our 2021 income figures were hit and we raised less money in 2021 than 2020. Encouragingly 2022 income appears to have increased to at least 2020 levels.

Despite this our fundraising team continued to perform miracles in raising funds to support our programmes. We are grateful to all those who donated and to those who volunteered on our behalf. Without your efforts and generosity we would not be able to continue our important work and we would have no funds to tackle the 'Hidden Pandemic'.

Fundraising highlights in 2021 include:

- £24,298 from National Lottery Awards for All to fund our Patient Support Service in all four nations.
- £90,000 (over 3 years) to support a PhD Studentship in antibiotic research.
- £87,000 from charitable trusts to support our Research Programme, including Small Research Grants & Early Career Development Awards.
- £30,000 corporate sponsorship to support our Annual Lecture and Student Engagement Programme.
- Building on our successful BBC Radio Four Appeal the previous year, we raised £21,000 from individual donors through match funding initiatives run by The Big Give Christmas Challenge and NET Crowdfunder.
- £16,000 raised from Community and Sporting Events, including London Marathon runner Carolyne Cross, the Lady Captain and members of Pike Hills Golf Club, Busy Bees Coffee Morning and a Pimms evening organised by our York Volunteer Group at Scampston Hall.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

FINANCIAL REVIEW

The consolidated gross income for the year was £409,696 (2020: £445,648). This year's income figure includes donated services of £80,771 (2020: £51,502), which when accounted for serves to highlight the challenging fundraising environment in 2021. Raised funds in 2021 dropped to £328,925 from £394,146 (a fall of £65,221).

The consolidated net movement in funds for the year was a deficit of £41,069 (2020: surplus of £96,225), a decrease of 143%, compounded by a significantly lower level of unrestricted funding income compared to previous years.

Going concern

Management works to an annual budget and has prepared a forecast to the end of December 2022, along with an outline budget and projections for 2023. These are used by management to ensure the organisation has sufficient funds in place to manage working capital in both the short term and longer term and enables the planning of resource allocation, organisational strategy, sustainability, and development.

Management has identified strong fundraising performance as crucial to positive cash flow management, particularly in relation to unrestricted funding. Fundraising plans and activities and future expenditure management have been reviewed, so as to better understand the impact of varying cashflows on the solvency of the organisation. Budgets have been set in line with the parameters in that review and are sufficient to ensure the organisation has adequate funds to meet its cash flow obligations to the end of 2023. Performance during 2021 highlighted the need to improve financial management and reporting processes within the organisation so that they are focused on agreed fundraising priorities and effective and responsive expenditure management. These areas have been reviewed and addressed by trustees and the organisation's management. A forward plan has been agreed, with a particular focus on building unrestricted reserves during 2023, while ensuring contingency plans are in place to manage any fundraising shortfalls. With these measures in place, trustees are confident about the organisation's ability to continue in operation for at least twelve months from the date of the financial statements.

On this basis, together with the unrestricted funding received in the first eight months of 2022, the Board has approved the preparation of the financial statements on the going concern basis.

Reserves policy

The trustees aim to maintain a minimum of free reserves equal to 3 months' core expenditure (approximately £60,000). Any funds over this sum will be used to fund the charity's objects.

The year-end level of free reserves was £33,884 (2020: £142,826). As noted above, organisational plans are in place to grow unrestricted reserves, including building a predictable and reliable funding base from individual and regular giving, as well as with community and corporate support, and through refocusing some of our fundraising priorities on essential expenditure related to our core mission.

PLANS FOR FUTURE PERIODS

In 2021 we developed a new five-year strategy, based on our own research on unmet need, supported with questionnaire data derived from three different Antibiotic Research UK stakeholder groups – supporters and donors; AMR scientists; and a cross-section of the population. We have identified and will work towards three main goals:

- Goal 1: Drive forward innovative solutions to drug-resistant infections
- Goal 2: Improve the lives of patients with drug-resistant infections and their families
- Goal 3: Raise awareness about the impact of drug-resistant infections

REPORT OF THE BOARD OF TRUSTEES

PLANS FOR FUTURE PERIODS (continued)

Innovative solutions to drug-resistant infections

In the short-term, we will:

- Continue to run the small research grants/career development awards programme and prioritise grants for basic research and/or health sciences projects, particularly focussing on seed funding and early-career projects.
- Support early-stage researchers to establish themselves in the AMR research field by creating a mentoring programme, connecting them with more experienced/established researchers.
- Raise the profile of the charity within the international AMR research field by actively participating in AMR events/congresses.
- Seek out funding partnerships to build on existing research projects, including the investigation of possible antibiotic combination therapies, alternatives to antibiotics or the development of an antibiotic resistance-breaker.
- Seek out partnerships for AMR projects related to the behavioural, social and/or applied health sciences (eg, a pilot trial in antibiotic stewardship), increasing the scope for collaboration with policymakers and healthcare providers.

In the longer term, we will partner with government, pharmaceutical companies and other funds or medical research charities to establish an AMR Research Fund to support projects in areas of greatest need.

Raising awareness

In the short-term, we will:

- Provide the patient voice in AMR policy through increased engagement with government AMR campaigns and by leading initiatives on social media; for example, a campaign for AMR to be listed as a cause of death on death certificates.
- Foster greater engagement with website users through the development of new informational resources.
- Increase engagement with universities by helping to establish undergraduate AMR societies (or by coordinating with existing science and health societies) and by providing support to organise outreach events.
- Promote wider awareness of the personal impact of antibiotic resistance, championing our patient support services and providing information on the actions individuals can take to reduce the prevalence of drug-resistant infections.
- Expand our network of volunteers through the development of an ambassador programme and provide volunteers with the skills needed to run support groups, fundraising events and local campaigns across the UK.
- Strengthen ties with corporate partners to raise awareness of the problem of drug-resistant infections and promote the health and wellbeing of their workforce.
- Help to create a Grand Alliance of AMR organisations, medical research and patient charities to create a unified voice to lobby governments on AMR policy.

This is an exciting opportunity to change the course of antibiotic resistance and save lives in the UK and across the world. All of this needs the continuing support and help of our existing stakeholders, supporters and funders, as well requiring help from new partners. We cannot do this alone and hope you will all join on us on this inspiring journey.

Our full strategy and business plan can be found on our website.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

REPORT OF THE BOARD OF TRUSTEES

TRUSTEES' RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS

The trustees are responsible for preparing the Report of the Board of Trustees' and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of income and expenditure of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2019 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees on 17 October 2022 and signed on their behalf by:



Simon Dukes

Signed on 20/10/22 @ 12:59

Mr S Dukes – Chair

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 December 2021 which comprise the statement of financial activities, balance sheet and relevant notes.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the charity's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW and ACCA.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



N P Clemit

Countersigned on 24/10/22 @ 15:59

Mr N Clemit ACA, FCCA
JWPCreers LLP
Chartered Accountants
Genesis 5
Church Lane
Heslington
York
YO10 5DQ

20 October 2022

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2021

	Notes	2021 Unrestricted funds £	2021 Restricted funds £	2021 Total funds £	2020 Total funds £
INCOME					
Donations and legacies:					
Donations and grants	2	59,721	3,179	62,900	88,968
Donated services	2	80,771	-	80,771	51,502
Charitable activities		59,186	177,707	236,893	261,651
Other trading activities:					
Membership fees		2,174	-	2,174	1,701
Fundraising events		26,958	-	26,958	41,811
Other interest		-	-	-	15
Total income		<u>228,810</u>	<u>180,886</u>	<u>409,696</u>	<u>445,648</u>
EXPENDITURE					
Raising funds					
Fundraising costs	3	98,064	-	98,064	78,611
Donated services		18,420	-	18,420	-
Charitable activities					
Charitable activities	4	242,556	5,130	247,686	223,554
Donated services		82,351	-	82,351	51,502
Total expenditure		<u>441,391</u>	<u>5,130</u>	<u>446,521</u>	<u>353,667</u>
Net (expenditure)/ income		(212,581)	175,756	(36,825)	91,981
Transfer between funds	8,9	103,642	(103,642)	-	-
Corporation tax receivable		(4,244)	-	(4,244)	4,244
Net movement in funds		(113,183)	72,114	(41,069)	96,225
Fund balance brought forward at 1 January 2021		<u>148,531</u>	<u>333,367</u>	<u>481,898</u>	<u>385,673</u>
Fund balance carried forward at 31 December 2021	8,9	<u><u>35,348</u></u>	<u><u>405,481</u></u>	<u><u>440,829</u></u>	<u><u>481,898</u></u>

All income and expenditure derives from continuing activities.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

BALANCE SHEETS AT 31 DECEMBER 2021

	Notes	Consolidated		Charity only	
		2021 £	2020 £	2021 £	2020 £
FIXED ASSETS					
Investments	5	-	-	1	1
CURRENT ASSETS					
Debtors and prepayments	6	4,105	17,970	1,711	12,172
Cash at bank and in hand		458,794	483,366	458,628	480,453
		462,899	501,336	460,339	492,625
LIABILITIES: Amounts falling due within one year	7	(22,070)	(19,438)	(20,975)	(16,433)
NET CURRENT ASSETS		440,829	481,898	439,364	476,192
NET ASSETS		440,829	481,898	439,365	476,193
THE FUNDS OF THE CHARITY					
Unrestricted funds		35,348	148,531	33,884	142,826
Restricted funds		405,481	333,367	405,481	333,367
TOTAL CHARITY FUNDS		440,829	481,898	439,365	476,193

Approved by the trustees on 17 October 2022 and signed on their behalf by:



Simon Dukes
Signed on 20/10/22 @ 12:59

Mr S Dukes - Chair

1. ACCOUNTING POLICIES

Basis of accounting

Antibiotic Research UK – Developing New Antibiotics is a charitable incorporated organisation in England. The address of the registered office is given in the charity information within the trustees' report of these financial statements.

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011, and UK Generally Accepted Accounting Practice.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are prepared in sterling which is the functional currency of the charity.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

Group financial statements

These financial statements consolidate the results of the charity and its wholly owned subsidiary ANTRUK Enterprises Limited on a line by line basis.

The gross income of the charity for the year was £409,696 and the result of the charity for the year was net deficit of £36,828.

Going Concern

The charity's financial statements are prepared on a going concern basis on the grounds that current and future sources of funding or support will be more than adequate for the charity's needs. The trustees have considered a period of twelve months from the date of approval of the financial statements and believe that no further disclosures relating to the charity's ability to continue as a going concern need to be made in the financial statements.

Fund accounting

Unrestricted funds are funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

Restricted funds are donations which the donor has specified are to be solely used for particular areas of the charity's work or for specific projects being undertaken by the charity.

Income

All income is included in the statement of financial activities when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donated services are accounted for at a reasonable estimate of their value to the charity and are included in the statement of financial activities as income when receivable.

Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2021

1. ACCOUNTING POLICIES (Continued)

Expenditure (continued)

Raising funds relates to costs incurred directly to generate donations. Charitable expenditure comprises those costs incurred by the charity in pursuit of its charitable object. Grants payable are charged in the year when the offer is conveyed to the recipient.

Tangible fixed assets and depreciation

Individual fixed assets costing £500 or more are capitalised at cost. Currently Antibiotic Research UK has no tangible fixed assets.

Debtors

Trade and other debtors are recognised at the settlement amount due. Prepayments are valued at the amount net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2. DONATIONS AND GRANTS

	2021 Unrestricted funds £	2021 Restricted funds £	2021 Total funds £	2020 Total funds £
Donations	25,720	-	25,720	52,248
Gift Aid	12,473	-	12,473	15,969
Online giving	21,528	3,179	24,707	20,751
	59,721	3,179	62,900	88,968
Donated services	80,771	-	80,771	51,502
	140,492	3,179	143,671	140,470

Donated services are legal services provided pro bono by Ashurst LLP, London and professional services by Costello Medical, Bow House Digital and ASF Alison Staples Fundraiser.

Included in donations are proceeds £6,933 gained from the dispersal of donated shares received during the year.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2021

3. RAISING FUNDS EXPENDITURE

	2021 Unrestricted funds £	2021 Restricted funds £	2021 Total funds £	2020 Unrestricted & total funds £
Fundraiser fees	109,494	-	109,494	76,154
Fundraising expenses	6,990	-	6,990	2,457
	<u>116,484</u>	<u>-</u>	<u>116,484</u>	<u>78,611</u>

Fundraising fees includes £18,420 (2020: £nil) of donated services.

4. CHARITABLE ACTIVITIES

	Note	2021 Unrestricted funds £	2021 Restricted funds £	2021 Total funds £	2020 Unrestricted & total funds £
Trading subsidiary	5	120,359	-	120,359	114,317
Patient support costs		-	3,519	3,519	-
Legal and professional fees		143,192	1,000	144,192	100,705
Consultancy fees		31,171	611	31,782	31,261
Accountancy		9,552	-	9,552	9,570
Printing, postage and stationery		1,522	-	1,522	3,009
Website and IT		12,926	-	12,926	12,031
Phone and internet		102	-	102	144
Computer and software		435	-	435	461
Insurance		578	-	578	522
Travel and subsistence		189	-	189	886
Bank and CAF charges		1,221	-	1,221	1,496
Recruitment costs		969	-	969	654
Annual lecture costs		2,691	-	2,691	-
		<u>324,907</u>	<u>5,130</u>	<u>330,037</u>	<u>275,056</u>

Legal and professional fees include £62,351 (2020: (£51,502) of donated services.

5. TRADING SUBSIDIARY

The wholly owned trading subsidiary, ANTRUK Enterprises Ltd (company number: 10396024), which was incorporated in England and Wales on 27 September 2016, provides funding to research projects concerning antibiotics. The charity owns the entire issued share capital of 1 ordinary share of £1. A summary of the trading results is shown below. Monies are granted from the charity to the trading subsidiary to fund research projects.

Summary profit and loss account

	2021 £	2020 £
Research costs and administration expenses	(120,359)	(114,317)
Income from group undertakings	120,361	110,780
Corporation tax (payable)/ repayable	(4,244)	4,244
Other interest	-	15
	<u>(4,242)</u>	<u>722</u>
Retained in subsidiary		
The assets and liabilities of the subsidiary were:		
Current assets	4,654	8,711
Creditors: amounts falling due within one year	(3,189)	(3,004)
	<u>1,465</u>	<u>5,707</u>
Total net assets		
Aggregate share capital and reserves	1,465	5,707

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2021

6. DEBTORS

	2021 Group £	2020 Group £	2021 Charity £	2020 Charity £
Other debtors	-	2,000	-	2,000
Prepayments and accrued income	1,711	10,172	1,711	10,172
VAT	2,394	1,554	-	-
Corporation tax	-	4,244	-	-
	<u>4,105</u>	<u>17,970</u>	<u>1,711</u>	<u>12,172</u>

7. CREDITORS DUE WITHIN ONE YEAR

	2021 Group £	2020 Group £	2021 Charity £	2020 Charity £
Accruals	22,070	19,438	18,881	16,433
Amounts owed to group undertakings	-	-	2,094	-
	<u>22,070</u>	<u>19,438</u>	<u>20,975</u>	<u>16,433</u>

8. RESTRICTED FUNDS

	2021			
	At 1.1.21 £	Income £	Expenditure £	At 31.12.21 £
Antibiotic Resistance Breakers	68,879	-	-	68,879
Patient Support	-	19,387	(4,519)	13,097
Combined Research 2019	55,030	-	(611)	54,419
Test Discs	64,269	-	(10,179)	54,090
Combined Research 2019 including Test Discs	62,824	-	-	62,824
Garfield Weston Foundation	25,000	-	-	25,000
Mutate Trial	-	48,812	-	8,457
Big give 2020 programmes	18,075	-	-	18,075
Combined Research 2020 including mutate trial & non-antibiotic alternatives	19,049	-	-	19,049
Combined Research 2021	-	51,727	-	27,795
TNL Scotland	2,017	5,976	-	-
TNL England	18,224	8,819	-	9,135
TNL Wales	-	4,593	-	4,101
TNL Northern Ireland	-	2,736	-	2,443
PhD student support	-	27,500	-	27,500
Reducing Antibiotic Prescribing	-	11,336	-	10,617
	<u>333,367</u>	<u>180,886</u>	<u>(5,130)</u>	<u>405,481</u>

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2021

8. RESTRICTED FUNDS (Continued)

Antibiotic Resistance Breakers (ARB) fund represents monies donated to fund the research into ARBs, this incorporates the Holbeck Charitable Trust funding as it was for the same cause.

Patient Support fund represents monies donated to fund a patient support officer whose role will be to develop a portfolio of patient support resources for people affected by antimicrobial resistance.

Combined Research 2019 fund represents monies donated towards a specific application for funds from Antibiotics Research that identified expenditure across three programmes. Research into new antibiotic therapies, research into non-antibiotic alternatives (Diamond), and a small research grants scheme.

Test Discs funds represents monies donated towards the next stage of research. The manufacture and circulation to partners of a test disk sensitivity kit for further testing.

Combined Research 2019 Including Test Discs fund represents monies donated towards both of the above two funds.

Garfield Weston Foundation fund represents monies donated towards the small research grants programmes.

Hobson Charity Ltd fund represents monies donated specifically for purchase of equipment.

Mutate Trial fund represents monies donated for the next phase of the MUTATE research programme which is working with hospital microbiology labs in a round robin evaluation of cefepime / sulbactam test discs.

Big Give 2020 Combined Projects fund represents monies donated through the online platform Big Give. Antibiotic Research identified the expenditure would cover patient support, original antibiotic resistance breakers and the small grants programmes.

Combined Research 2020 Including Mutate Trial fund represents monies donated towards a specific application for funds from Antibiotics Research that identified expenditure across three programmes. Antibiotic resistance breakers, recruitment of more microbiology labs to the MUTATE project and small grants research.

Combined Research 2020 Including Mutate Trial & Non-Antibiotic Alternatives fund represents monies donated to the above 2020 combination and includes expenditure on Non-Antibiotic alternatives.

Combined Research 2021 fund represents monies donated towards small research grants and early careers development awards.

TNL Scotland fund represents a National Lottery Award, monies donated are to be used to give Scottish Support Network for People Affected by antibiotic resistant infections in Aberdeen.

TNL England fund represents a National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in England.

TNL Wales fund represents a National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in Wales.

TNL Northern Ireland fund represents a National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in Northern Ireland.

PhD student support fund represents monies donated by the Troutsdale Trust to support a PhD student.

Reducing Antibiotic Prescribing through triaging using Point of Care testing fund represents monies donated for the Study Protocol Development and planning for the scaled up roll out of the study.

The transfers represent the money spent in ANTRUK Enterprises Ltd on these projects.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2021

8. RESTRICTED FUNDS (Continued)

	2020				
	At 1.1.20 £	Income £	Expenditure £	Transfer £	At 31.12.20 £
Antibiotic Resistance Breakers	62,879	6,000	-	-	68,879
Patient Support	8,120	4,190	-	(12,310)	-
Combined Research 2019	58,756	20,700	-	(24,426)	55,030
Test Discs	57,186	9,200	-	(2,117)	64,269
Combined Research 2019 including Test Discs	67,189	1,838	-	(6,203)	62,824
Garfield Weston Foundation	-	25,000	-	-	25,000
Hobson Charity Ltd	-	5,000	-	(5,000)	-
Mutate Trial	-	23,920	-	(23,920)	-
Big give 2020 programmes	-	18,075	-	-	18,075
Combined Research 2020 including mutate trial	-	184	-	(184)	-
Combined Research 2020 including mutate trial & non-antibiotic alternatives	-	23,920	-	(4,871)	19,049
TNL Scotland	-	3,220	-	(1,203)	2,017
TNL England	-	29,105	-	(10,881)	18,224
	<u>254,130</u>	<u>170,352</u>	<u>-</u>	<u>(91,115)</u>	<u>333,367</u>

9. UNRESTRICTED FUNDS

UNRESTRICTED FUNDS		2021				
	At 1.1.21 £	Income £	Expenditure £	Transfer £	Tax £	At 31.12.21 £
General unrestricted funds	142,825	228,810	(321,033)	(16,718)	-	33,884
Non-charitable trading funds	5,706	-	(120,358)	120,360	(4,244)	1,464
	<u>148,531</u>	<u>228,810</u>	<u>(441,391)</u>	<u>103,642</u>	<u>(4,244)</u>	<u>35,348</u>
		2020				
	At 1.1.20 £	Income £	Expenditure £	Transfer £	Tax £	At 31.12.20 £
General unrestricted funds	126,558	275,281	(239,349)	(19,665)	-	142,825
Non-charitable trading funds	4,985	15	(114,318)	110,780	4,244	5,706
	<u>131,543</u>	<u>275,296</u>	<u>(353,667)</u>	<u>91,115</u>	<u>4,244</u>	<u>148,531</u>

The transfers in both years represents the funds (both restricted for the projects and unrestricted for general expenses) transferred into ANTRUK Enterprises Limited.

ANTIBIOTIC RESEARCH UK – DEVELOPING NEW ANTIBIOTICS

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2021

10. ANALYSIS OF NET ASSETS BETWEEN FUNDS

Fund balances at 31 December 2021 are represented by:	Unrestricted funds £	Restricted funds £	Total £
GROUP			
Current assets	57,418	405,481	462,899
Creditors: amounts falling due in less than one year	(22,070)	-	(22,070)
Total net assets	35,348	405,481	440,829
CHARITY			
Investments	1	-	1
Current assets	54,858	405,481	460,339
Creditors: amounts falling due in less than one year	(20,975)	-	(20,975)
Total net assets	33,884	405,481	439,365
Fund balances at 31 December 2020 are represented by:	Unrestricted funds £	Restricted funds £	Total £
GROUP			
Current assets	167,969	333,367	501,336
Creditors: amounts falling due in less than one year	(19,438)	-	(19,438)
Total net assets	148,531	333,367	481,898
CHARITY			
Investments	1	-	1
Current assets	159,258	333,367	492,625
Creditors: amounts falling due in less than one year	(16,433)	-	(16,433)
Total net assets	142,826	333,367	476,193

NOTES TO THE CONSOLIDATED ACCOUNTS - 31 DECEMBER 2021

11. **TRUSTEES' REMUNERATION AND EXPENSES**

No remuneration was paid or payable directly or indirectly out of the funds of the charity for the period to any trustee or to any person or persons known to be connected with any of them for acting as a trustee.

No trustees were reimbursed expenses (2020: no trustees).

12. **RELATED PARTY TRANSACTIONS**

Garner Consulting Services received £31,782 (2020: £31,261) for consultancy services and received £31,782 (2020: £31,261) for research project management costs from ANTRUK Enterprises Ltd. As ANTRUK Enterprises Ltd is VAT registered the net cost was £26,485. The total cost to the group was £58,267 (2020: £57,312). Professor C Garner (Chief Executive of Antibiotic Research UK) and his wife are the partners in Garner Consulting Services. Of this amount £5,419 was owed to Garner Consulting Services at the year end (2020: £5,210).

Azets of which J A Farmer is a partner received £7,180 for accounting services. (2020: £6,200)

Ashurst LLP, of which N Stalbow is a partner, have provided pro bono services to the value of £1,536 (2020: £26,412).

The aggregated donations made by the trustees were £1,025 (2020: £2,000).

13. **GRANT COMMITMENTS**

Small grants committed at 31 December 2021 were £108,795 (2020: £85,028).

Grant income committed at 31 December 2021 was £30,000 within 1 year (2020: £nil) and £30,000 within 2 years (2020: £nil).

Accounts



Antibiotic
RESEARCH UK

2020 Impact Report
& Financial Review

FIGHTING

ANTIBIOTIC RESISTANCE,

TODAY AND TOMORROW

CONTENTS

Antibiotic Resistance and Us	4
Sharon's Story	5
Science and Research	6
Patient Support	7
Education	8
Fundraising	9
Plans for the Future	10
A Big 'Thank You'	11
2020 Financial Statements	12-28



REFERENCE AND

ADMINISTRATIVE INFO

Registered charity name:

Antibiotic Research UK - Developing New Antibiotics

Registered charity number:

1157884

Other names:

ANTRUK

GET IN TOUCH

Antibiotic Research UK
Genesis 5
Church Lane
Heslington
York
YO10 5DQ

T: 01904 468719

E: info@antibioticresearch.org.uk

PRESS ENQUIRIES

Please contact

T: +44 (0)1904 468719

E: media@antibioticresearch.org.uk

FIND US ONLINE

www.antibioticresearch.org.uk



@1ANTRUK



AntibioticResearchUK



Antibiotic Research UK





The year 2020 will be remembered as an annus horribilis for the world. Despite the tragedy and disruption, we have continued to fight for the future of modern medicine. One silver lining is the way the pandemic shone a light on the importance and value of scientists and researchers.

It has been a frightening time for people with drug-resistant infections. We still don't know how many lives will have been lost to secondary bacterial infections at this point.

We did not have time to lament the expense of paused lab-research programmes, as the people we support needed us more than ever. We established ourselves as a trusted source of information and extended our patient support service to help as many people as possible.

I was delighted to welcome Simon Dukes as our Trustee Chair Designate during this time, bringing a wealth of experience from the Civil Service and the Pharmaceutical Services Negotiating Committee.

Despite the cessation of all face-to-face fundraising activities, we were relieved to maintain a comparable income with 2019. We received our first National Lottery grant and ran a fantastic BBC Radio 4 Appeal. This is testament to each and every person, business and organisation that supported us in 2020, as well as our fantastic team of innovative fundraisers who pivoted to virtual fundraising with enthusiasm.

Stay safe and please help us save the world from what just might be the next pandemic.

Professor Colin Garner, Chief Executive.



Antibiotic resistance and us

Antibiotics are a miracle of modern medicine. They kill bacteria that would otherwise cause severe and often fatal infections. Antibiotics are what make operations, chemotherapy, childbirth and dental work safe.

Tragically, we haven't looked after our antibiotics, and new variants of bacteria are finding ways to resist them. Increasingly difficult-to-treat infections are arising, and new antibiotics are not easy to develop.

The World Health Organisation predicts that by 2050, more than 10 million people will die from antibiotic-resistant infections each year.

But it wasn't until 2020, and COVID-19, that we saw what millions of deaths from an infectious disease might look like. Our greatest hope as a charity is that scientists, the general public and policymakers will see the parallels between the viral pandemic of 2020 and the ever-growing risk of a bacterial pandemic in the near future, and that they will act now.

Our role remains the same, but with renewed vigour. Antibiotic Research UK exists to save the future of antibiotics - the future of modern medicine. We will do so by investing in research and educating people about this issue. We also stand side by side with those affected by antibiotic-resistant infections, providing support and advice, and helping them campaign for meaningful change.


The work and the impact you read about on these pages is entirely down to people like you. Thank you.

Meet Sharon

Sharon is no stranger to medical issues, having survived three heart attacks in her 30s, among other things. She lives with her three teenagers and her husband, who have been a real source of support during 2020, especially as she is considered 'high risk' and has had to isolate.

In 2019, Sharon experienced a rapid deterioration in her health when she developed sinusitis, a bacterial urinary tract infection and then sepsis and septicaemia (caused by the infection) within a short space of time. She had had sepsis before; this time, however, during her treatment with oxygen and intravenous antibiotics, a clinician told her that she had ESBL *E. coli*, and they moved her to her own isolated room.

"You can feel the life draining out of your body."



"Sepsis, caused by a bacterial infection in my case, makes you feel like you are dying. You can feel the life draining out of your body. It was scary to spend three weeks alone in intensive care without any idea why."

Sharon was given antibiotics that are saved for the most serious and difficult to treat bacterial infections. But when she eventually returned home to continue her recovery, she still hadn't been given any answers.

"What does ESBL mean? Why did I have to isolate - can I pass it on to my kids? Will I end up in hospital again?"



She also struggled with the after-effects of sepsis itself:

"I found it very hard to get back to being myself again. I hardly laughed, I no longer enjoyed jokes and I lost my enjoyment in things I had liked."

Feeling let down by the lack of information from medical professionals, Sharon called Arlene, our Patient Support Officer (see page 7), who was able to provide her with some of the answers she was seeking, and a listening ear.

"I was lucky to be able to isolate during the pandemic with my three teenagers and my husband, and to know that Arlene was just a call away if I needed her. I've learned to live with most of the fear, but I hope that my story - and Arlene's support - will help others to feel less afraid and alone."

Sharon, and others just like her, are the reason why we strive every day to save our antibiotics, educate people about drug resistance and provide support to people affected by resistant infections.

Science and research


Our aims

We are tackling drug-resistant infections through research by:

1. Breaking the mechanisms by which bacteria resist the effect of antibiotics
2. Identifying new treatments that we can use instead of precious antibiotics
3. Continuing to provide funding for our Small Research Grants/Career Development Awards programme to support academic researchers across the UK working in the field

This year, we saw how science can fight back against infectious diseases. Without the work of scientists, there would be no hope of an end to the pandemic. That is why it's so important for us to continue to support research into drug-resistant infections; it just might help prevent the next pandemic.

Our pioneering Small Research Grant programme continued to support leading scientists at British academic institutions. Findings from our 2018 grant-funded projects were shared at virtual conferences throughout 2020, and published in leading journals such as the *Archives of Disease in Childhood* and *Preventive Veterinary Medicine*.



Thanks to the generosity of our funders, during this year the Trustees allocated £200,000 to be spent via our 2021 research grants. We also prepared for the publication of the results of the DIAMOND trial, a pilot clinical trial conducted in China on a non-antibiotic treatment for infections. The trial demonstrated the feasibility of this type of study, and paves the way for larger trials in the future.

We continued to support work investigating a combination of antibiotic and resistance-breaking medications. UK hospitals have agreed to participate, using bacteria from patients, which we sincerely hope will progress to clinical trials.

**Your funding is what makes this research possible.
Thank you.**

Patient Support

Arlene, our fantastic Patient Support Officer, helped over 100 people like Sharon in 2020.

Arlene and our network of volunteers have been speaking at conferences (2020 BioInfect), symposia (NESTA UTI Challenge) and on podcasts (The Steward) to help raise awareness of the human cost of the spread of antibiotic resistance.

We also welcomed a second member to our Patient Support Team, launched a closed community on Facebook for peer-to-peer support and trialed Zoom group calls.

While the solution to the problem will likely be discovered in a lab and administered in hospitals, the impact of antibiotic resistance is felt inside homes around the world. That side of the story is the reason for all our hard work, and it's one we shone a spotlight on through our collection of real-life stories.

"The unwelcome arrival of COVID-19 has led to calls about symptoms lasting weeks, to discuss fears about developing secondary bacterial infections, or having an ongoing chronic condition including infection and fear that contracting COVID-19 might cause severe illness".

Arlene Brailey, Patient Support Officer.

"I have talked to Arlene quite a few times - she's so kind and understanding. I struggled to get the medical appointments I needed during the pandemic. I have learned to become my own doctor and to listen to my body, but having someone to talk to who understands without judging has been a lifeline. I talk to her about everything - my health, but also my life."


Sharon (page 5)

Our Patient Support Team has also been busy producing resources to help people learn more about specific antibiotic-resistant infections and their treatments. Nearly 20,000 website visitors used those resources in 2020.



Education

Spreading the word about antibiotic resistance



SOCIAL MEDIA



THE WEBSITE

nearly
200,000
users
(a 200% increase on
the previous year)



45,000

views of our page
about common
infections

25,000

views of our first article
about COVID-19,
bacterial infections
and antibiotic
resistance

7,000

views of our Ask
ANTRUK feature



**We were approaching our
one-millionth lifetime page
view at the end of the year!**



Here's what we produced in 2020:

- Don't Dare To Share campaign, about sexually transmitted infections. *Covered on regional radio and TV and in magazines.*
- Advances In Antimicrobial Optimisation, our first ever online lecture, watched by 70 academics, clinicians and members of the public. *By Professor Alison Holmes, Imperial College London.*
- Our inaugural Great University Science Quiz, encouraging AMR Societies across the UK. *Also raising £2,000 and featuring celebrity scientist quizmasters.*
- Diagnosing Antibiotic Allergies leaflet. *Based on the Grampian Health Board's leaflet, with kind permission.*

Here's what we collaborated on:

- We contributed to Manchester University's online course about antibiotic resistance, completed by 1,500 people in 85 countries.
- We contributed to Pfizer's 'Change The Course' campaign for World Antimicrobial Resistance Awareness Week.
- Dr Roger Harrison (a member of our Education Committee) also led a successful bid to Manchester Wellcome Institutional Strategic Support Fund, to support science students working with communities to provide education on antibiotic resistance.

Fundraising

There's no doubt about it, 2020 was a very challenging year. But instead of telling you about all of the tea parties, marathons, charity pub quizzes and everything else that was cancelled, we want to shout about the creative ways that our supporters raised money instead.

We were delighted to retain the support of most of our existing Trust and Foundation supporters, and to welcome funding from 15 new ones, too. In total, we raised more than £256,000 from Trusts and Foundations. Thank you!

No marathon? No problem! Our 2.6 challenge inspired people to get involved, including:

- Hector the half-marathon hero (31 half marathons in as many days!)
- Our Head of Fundraising, Alison, leading by example and walking a marathon up and down her own street
- Members of The University of Manchester AMR Society also ran the virtual Purple Wave (part of a rescheduled, virtual Great Manchester Run).

We have missed our Great British Tea Parties, especially during World Antimicrobial Resistance Awareness Week, but did you hear us on Radio 4?! Our BBC Radio 4 Appeal, presented by BBC Inside Science's Dr Adam Rutherford raised a spectacular £57,000.

And our supporters really got into the spirit of Christmas, hitting our Big Give Christmas Challenge 'double your donation' campaign target of £18,000.

What's more, we've learned a thing or two about online/individual fundraising challenges.

- Our inaugural Great University Science Quiz raised over £2,000
- At-home fundraising and sporting activities raised £40,000
- Our supporters have really made the most of it, too! From Cliff, setting himself a wellbeing photography challenge to Chris and his Grateful Dead fan club, we've been impressed with a diverse range of digital fundraising efforts.

The York Voluntary Group were supported by very generous donations from those invited to their cancelled National Railway Museum fundraiser, which managed to raise £20,000 without even happening!

We were over the moon to receive our first ever National Lottery award from The National Lottery Community Fund Scotland Awards for All and funding from the Coronavirus Community Support Fund, also distributed by The National Lottery Community Fund (England). Thank you to the Government, and of course to National Lottery players! The grand total of £35,136 was a vital lifeline for our online information and support services at this time.

Together, we raised £445,648 under some of the most difficult circumstances imaginable.

THANK YOU!

Plans for the future

Preventing the next pandemic

We are naturally looking to the future with a great deal of hope after a very challenging year. The tail end of this pandemic provides us with an opportunity to raise awareness of the fact that the next one could be caused by antibiotic-resistant infections, unless we all play our part.

The suspension of some academic lab work in 2020 means that there is a huge pent up demand for research funding. During 2020 we agreed to set aside £200,000 for Small Research Grants/Career Development Awards programme to fund UK academics; we look forward to allocating those funds where they will have the most impact soon.

From a fundraising perspective, World AMR Awareness Week will be back with a bang with tea parties and more. We're thrilled to be continuing our Great University Science Quiz after our successful inaugural event, and we are developing a dedicated student area on our website to further nurture and tap into the enthusiasm and potential of the UK student community. Of course, sporting events are also returning and we have places for both the Vitality Big Half Marathon and the Virgin Money London Marathon.


We will work hard to expand our Patient Support offering to provide more help to those that need it. As well as continuing to provide support and information to people affected by antibiotic-resistant infections, we will also continue to share their stories.

It is so important to show the world that anybody can be affected by these infections, so we must all work together to help overcome them. As well as giving our supporters a voice, we will raise awareness of our charity and the work we do through strategic media campaigns.

We hope that we have showcased our ability to adapt in the face of great adversity, thanks to our fantastically supportive donors and our ever-creative fundraisers. We will continue to apply determination and innovation in all aspects of our work.

Most importantly, we will continue to nurture and cherish the partnerships that allow Antibiotic Research UK to achieve much, much more than we would on our own. Thank you for being a part of something so important. Together, we will save modern medicine.





Take one simple action today to help protect your loved ones' futures

Over 700,000 people die from drug-resistant infections every year. It is predicted that we will reach 10 million annual deaths by 2050 if we don't act now. We are the first charity in the world dedicated to fighting antibiotic resistance, but we can't do it without you.

By taking action today and remembering Antibiotic Research UK in your Will, you are ensuring that we will be here to continue fighting for the next generation - and the ones after that, too.

If you would like to speak to someone about leaving a gift in your Will, however big or small, please contact our Legacy fundraiser, Kate Fordham.

Email: kate.fordham@antibioticresearch.org.uk
Telephone: 07914 324181

A big thank you!

Thank you to our wonderful supporters for your continued support, and thank you to The Sir James Reckitt Charity, Sylvia Waddilove Foundation and other Trusts and Foundations who supported our vital work in 2020. A special mention to those who made our Radio 4 appeal such a success. We really couldn't carry out our vital work without you. And of course, a huge thank you to everyone who works for the charity in a paid or voluntary capacity.

Fundraisers:

- Ladies' Section of the Pikes Hill Golf Club in York chose Antibiotic Research UK as Charity of the Year raised more than £1,300 before COVID-19 put a stop to things - and we are thrilled that they are continuing to support us in 2021.
- BBC Radio 4 appeal.
- The National Lottery Community Fund Scotland Awards for All.
- The National Lottery Community Fund Coronavirus Community Support Fund distributed by The National Lottery Community Fund. Thanks to the Government for making this possible.



theBigGive



Garfield Weston
FOUNDATION

Report of the Board of Trustees

The trustees present their report and the financial statements of the charity for the year ended 31 December 2020. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) “Accounting and Reporting by Charities” in preparing the annual report and financial statements of the charity.

The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity’s governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published in October 2019.

OBJECTIVES & ACTIVITIES

Antibiotic Research UK aims to protect and promote the health of the public, in particular by sponsoring research into the diagnosis, treatment and cure of antibiotic-resistant bacterial infectious diseases, ensuring responsible and sustainable development and deployment of the findings of such research, and raising awareness through public-facing activities and the promotion of networks to share experience of such matters.

Antibiotic Research UK was created by a group of internationally recognised scientists and clinicians expert in antibiotic resistance in 2014. The experts were drawn from a network of representatives from fourteen of the United Kingdom’s top universities as well as from specialty pharmaceutical companies and organisations. Antibiotic Research UK has set itself ambitious goals of developing one new antibiotic therapy by the early 2020’s with subsequent therapies coming on-stream over the next decades.

PUBLIC BENEFIT

The trustees have due regard to the Charity Commission’s guidance on public benefit, and ensure that the activities of the organisation meet those requirements.

ACHIEVEMENT AND PERFORMANCE

Included in the impact report.

FINANCIAL REVIEW

The consolidated gross income for the year was £445,648 (2019: £420,809). This year's income figure includes donated services of £51,502 (2019: £58,454).

The consolidated net movement in funds for the year was £96,225 (2019: £41,882), an increase of 130%.

Reserves policy

The year-end level of free reserves was £142,825 (2019: £126,558). The trustees aim to maintain a minimum of free reserves equal to 6 months core expenditure and funds over this sum will be used to fund the charity's objects.

STRUCTURE, GOVERNANCE & MANAGEMENT

Antibiotic Research UK is a registered charitable incorporated organisation as of 16 July 2014 and is governed by its constitution, which was amended and approved at the 2016 AGM on 24 October 2016 and at the 2019 AGM on 24 October 2019.

Trustees recruitment and appointment

Trustees are appointed and re-elected in accordance with the provisions set out in the constitution. There should be a minimum of three trustees and a maximum of twelve.

The trustees will retire from office after a full term (3 years) at the next annual general meeting. Any trustee at the AGM 24 October 2019 were deemed to have commenced their first three-year term on that date. A trustee can seek re-election for a further term of office but not a third term without an interval of a year.

Trustees can only be formally appointed as a trustee at the annual general meeting although a person can attend meetings as an observer prior to this point.

Trustees induction and training

The charity trustees will make available to each new charity trustee, on or before his or her first appointment; a copy of the constitution and any amendments made to it; and a copy of the CIO's latest trustees' annual report and statement of accounts.

PLANS FOR FUTURE PERIODS

Included in the impact report.

Report of the Board of Trustees

OUR TRUSTEES

- ➔ Mr N Stalbow Interim chair (until 1 January 2021)
- ➔ Mr J A Farmer Treasurer
- ➔ Professor C Bond
- ➔ Dr R Bowden (Resigned November 2020)
- ➔ Professor C Dowson
- ➔ Ms E Lyon
- ➔ Ms Y Thakurdas (Resigned 1 January 2021)

Observer

- ➔ Mr S Dukes Chair designate (from 1 January 2021)
- ➔ Mr A Burgess Founding chairman

Chief Executive Professor R C Garner

Patron

The Most Revd & Rt Hon the Lord Archbishop of York, J Sentamu (to June 2020)

ADVISORS

Principal Bankers:

Lloyds Bank PLC
2 Pavement
York
YO1 9UP

Independent Examiner:

Mr N Clemit ACA, FCCA
JWPCreers LLP
Chartered Accountants
Genesis 5
Church Lane
Heslington
York
YO10 5DQ

Report of the Board of Trustees

TRUSTEES RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS

The trustees are responsible for preparing the Report of the Board of Trustees' and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of income and expenditure of the charity for that period. In preparing these financial statements, the trustees are required to:

- ➔ select suitable accounting policies and then apply them consistently;
- ➔ observe the methods and principles in the Charities SORP 2019 (FRS 102);
- ➔ make judgements and estimates that are reasonable and prudent;
- ➔ state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- ➔ prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees on 16/07/2021 and signed on their behalf by:



Mr N Stalbow - Trustee

Independent examiner's report to the Trustees

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 December 2020 which comprise the statement of financial activities, balance sheet and relevant notes.

RESPONSIBILITIES AND BASIS OF REPORT

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the charity's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable directions given by the Charity Commission under section 145(5)(b) of the Act.

INDEPENDENT EXAMINER'S STATEMENT

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am a member of ACCA.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- ① accounting records were not kept in respect of the charity as required by section 130 of the Act; or
- ② the accounts do not accord with those records; or
- ③ the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Mr N Clemit

.....
16/07/2021

Mr N Clemit ACA, FCCA
JWPCreers, LLP Chartered Accountants
Genesis 5, Church Lane, Heslington, York, YO10 5DQ

Consolidated statement of financial activities for the year ended 31 December 2020

	Notes	2020 Unrestricted funds (£)	2020 Restricted funds (£)	2020 Total funds (£)	2019 Total funds (£)
INCOME					
Donations and legacies:					
Donations and grants	2	140,470	-	140,470	153,732
Charitable activities		91,299	170,352	261,651	236,100
Other trading activities:					
Membership fees		1,701	-	1,701	556
Fundraising events		41,811	-	41,811	30,421
Other interest		15	-	15	-
Total income		<u>275,296</u>	<u>170,352</u>	<u>445,648</u>	<u>420,809</u>
EXPENDITURE					
Raising funds	3	78,611	-	78,611	98,834
Charitable activities	4	275,056	-	275,056	283,970
Total expenditure		<u>353,667</u>	<u>-</u>	<u>353,667</u>	<u>382,804</u>
Net income/(expenditure)		<u>(78,371)</u>	<u>170,352</u>	<u>91,981</u>	<u>38,005</u>
Transfer between funds	8,9	91,115	(91,115)	-	-
Corporation tax receivable		4,244	-	4,244	3,877
Net movement in funds		<u>16,988</u>	<u>79,237</u>	<u>96,225</u>	<u>41,882</u>
 Fund balance brought forward at 1 January 2019		 <u>131,543</u>	 <u>254,130</u>	 <u>385,673</u>	 <u>343,791</u>
Fund balance carried forward at 31 December 2020	8,9	<u>148,531</u>	<u>333,367</u>	<u>481,898</u>	<u>385,673</u>

All income and expenditure derive from continuing activities.

Balance Sheets as at 31 December 2020

	Notes	Consolidated		Charity only	
		2020 (£)	2019 (£)	2020 (£)	2019 (£)
FIXED ASSETS					
Investments	5	-	-	1	1
CURRENT ASSETS					
Debtors and prepayments	6	17,970	20,957	12,172	14,447
Cash at bank and in hand		483,366	383,074	480,453	381,211
		<u>501,336</u>	<u>404,031</u>	<u>492,625</u>	<u>395,658</u>
LIABILITIES					
Amounts falling due within 1 year	7	(19,438)	(18,358)	(16,433)	(14,971)
		<u>481,898</u>	<u>385,673</u>	<u>476,192</u>	<u>380,687</u>
NET CURRENT ASSETS					
		<u>481,898</u>	<u>385,673</u>	<u>476,193</u>	<u>380,688</u>
NET ASSETS					
THE FUNDS OF THE CHARITY					
Unrestricted funds		148,531	131,543	142,826	126,559
Restricted funds		<u>333,367</u>	<u>254,130</u>	<u>333,367</u>	<u>254,129</u>
TOTAL CHARITY FUNDS					
		<u><u>481,898</u></u>	<u><u>385,673</u></u>	<u><u>476,193</u></u>	<u><u>380,688</u></u>

Approved by the trustees on 16/07/2021 and signed on their behalf by:

Mr J A Farmer

Mr J A Farmer - Treasurer

1. ACCOUNTING POLICIES

Basis of Accounting

Antibiotic Research UK – Developing New Antibiotics is a charitable incorporated organisation in England. The address of the registered office is given in the charity information within the trustees' report of these financial statements.

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011, and UK Generally Accepted Accounting Practice.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are prepared in sterling which is the functional currency of the charity.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

Group financial statements

These financial statements consolidate the results of the charity and its wholly owned subsidiary ANTRUK Enterprises Limited on a line by line basis.

The gross income of the charity for the year was £445,633 and the result of the charity for the year was net income of £95,505.

Notes to the consolidated accounts for the year ended 31 December 2020

Fund accounting

Unrestricted funds are funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

Restricted funds are donations which the donor has specified are to be solely used for particular areas of the charity's work or for specific projects being undertaken by the charity.

Income

All income is included in the statement of financial activities when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donated services are accounted for at a reasonable estimate of their value to the charity and are included in the statement of financial activities as income when receivable.

Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Raising funds relates to costs incurred directly to generate donations. Charitable expenditure comprises those costs incurred by the charity in pursuit of its charitable object. Grants payable are charged in the year when the offer is conveyed to the recipient.

Tangible fixed assets and depreciation

Individual fixed assets costing £500 or more are capitalised at cost. Currently Antibiotic Research UK has no tangible fixed assets.

Debtors

Trade and other debtors are recognised at the settlement amount due. Prepayments are valued at the amount net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2. DONATIONS & GRANTS

	2020 Unrestricted & Total funds (£)	2019 Unrestricted & Total funds (£)
Donations	52,248	60,557
Gift aid	15,969	10,181
Online giving	20,751	24,540
Donated services	51,502	58,454
	<u>140,470</u>	<u>153,732</u>

Donated services are legal services provided pro bono by Ashurst LLP, London and professional services by Costello Medical.

3. RAISING FUNDS EXPENDITURE

	2020 Unrestricted & Total funds (£)	2019 Unrestricted & Total funds (£)
Fundraiser fees	76,154	76,515
Fundraising expenses	2,457	22,319
	<u>78,611</u>	<u>98,834</u>

Notes to the consolidated accounts for the year ended 31 December 2020

4. CHARITABLE ACTIVITIES

	Notes	Unrestricted funds (£)	Restricted funds (£)	2020 Total funds (£)	2019 Unrestricted & Total funds (£)
Trading subsidiary	5	114,318	-	114,318	112,630
Legal and professional fees		100,705	-	100,705	106,904
Consultancy fees		31,261	-	31,261	30,229
Accountancy		9,570	-	9,570	8,485
Printing, postage and stationery		3,009	-	3,009	7,450
Website and IT		12,031	-	12,031	8,031
Phone and internet		144	-	144	473
Computer and software		461	-	461	1,574
Insurance		522	-	522	522
Travel and subsistence		886	-	886	4,513
Subscriptions		-	-	-	117
Bank and CAF charges		1,496	-	1,496	1,211
Sundry expenses		-	-	-	111
Trustee expenses		-	-	-	362
Recruitment costs		653	-	653	1,358
		<u>275,056</u>	<u>-</u>	<u>275,056</u>	<u>283,970</u>

Notes to the consolidated accounts for the year ended 31 December 2020

5. TRADING SUBSIDIARY

The wholly owned trading subsidiary, ANTRUK Enterprises Ltd (company number: 10396024), which was incorporated in England and Wales on 27 September 2016, provides funding to research projects concerning antibiotics. The charity owns the entire issued share capital of 1 ordinary share of £1. A summary of the trading results is shown below. Monies are granted from the charity to the trading subsidiary to fund research projects.

SUMMARY PROFIT & LOSS ACCOUNT

	2020 (£)	2019 (£)
Research costs and administration expenses	(114,317)	(112,630)
Income from group undertakings	110,780	112,899
Corporation tax receivable	4,244	3,877
Other interest	15	-
Retained in subsidiary	722	4,146

THE ASSETS AND LIABILITIES OF THE SUBSIDIARY WERE:

Current assets	8,711	8,373
Creditors: amounts falling due within one year	(3,004)	(3,388)
Total net assets	5,707	4,985
Aggregate share capital and reserves	5,707	4,985

6. DEBTORS

	2020 Group (£)	2019 Group (£)	2020 Charity (£)	2019 Charity (£)
Other debtors	2,000	13,000	2,000	13,000
Prepayments and accrued income	10,172	1,447	10,172	1,447
VAT	1,554	2,648	-	-
Corporation tax	4,244	3,862	-	-
	17,970	20,957	12,172	14,447

Notes to the consolidated accounts for the year ended 31 December 2020

7. CREDITORS DUE WITHIN ONE YEAR

	2020 Group (£)	2019 Group (£)	2020 Charity (£)	2019 Charity (£)
Accruals	19,438	18,358	16,433	14,971
	<u>19,438</u>	<u>18,358</u>	<u>16,433</u>	<u>14,971</u>

8. RESTRICTED FUNDS 2020

	At 1.1.20 (£)	Income (£)	2020 Expenditure (£)	Transfer (£)	At 31.12.20 (£)
Antibiotic Resistance Breakers	62,879	6,000	-	-	68,879
Patient Support	8,120	4,190	-	(12,310)	-
Combined Research 2019	58,756	20,700	-	(24,426)	55,030
Test Discs	57,186	9,200	-	(2,117)	64,269
Combined Research 2019 including Test Discs	67,189	1,838	-	(6,203)	62,824
Garfield Weston Foundation	-	25,000	-	-	25,000
Hobson Charity Ltd	-	5,000	-	(5,000)	-
Mutate Trial	-	23,920	-	(23,920)	-
Big Give 2020 programmes	-	18,075	-	-	18,075
Combined Research 2020 including mutate trial	-	184	-	(184)	-
Combined Research 2020 including mutate trial & non-antibiotic alternatives	-	23,920	-	(4,871)	19,049
TNL Scotland	-	3,220	-	(1,203)	2,017
TNL England	-	29,105	-	(10,881)	18,224
	<u>254,130</u>	<u>170,352</u>	<u>-</u>	<u>(91,115)</u>	<u>333,367</u>

Notes to the consolidated accounts for the year ended 31 December 2020

Antibiotic Resistance Breakers (ARB) fund represents monies donated to fund the research into ARBs, this incorporates the Holbeck Charitable Trust funding as it was for the same cause.

Patient Support fund represents monies donated to fund a patient support officer whose role will be to develop a portfolio of patient support resources for people affected by antimicrobial resistance.

Combined Research 2019 fund represents monies donated towards a specific application for funds from Antibiotics Research that identified expenditure across three programmes. Research into new antibiotic therapies, research into non-antibiotic alternatives (Diamond), and a small research grants scheme.

Test Discs funds represents monies donated towards the next stage of research. The manufacture and circulation to partners of a test disc sensitivity kit for further testing.

Combined Research 2019 Including Test Discs fund represents monies donated towards both of the above two funds.

Garfield Weston Foundation fund represents monies donated towards the small research grants programmes.

Hobson Charity Ltd fund represents monies donated specifically for purchase of equipment.

Mutate Trial fund represents monies donated for the next phase of the MUTATE research programme which is working with hospital microbiology labs in a round robin evaluation of cefepime / sulbactam test discs.

Big Give 2020 Combined Projects fund represents monies donated through the online platform Big Give. Antibiotic Research identified the expenditure would cover patient support, original antibiotic resistance breakers and the small grants programmes.

Combined Research 2020 Including Mutate Trial fund represents monies donated towards a specific application for funds from Antibiotics Research that identified expenditure across three programmes. Antibiotic resistance breakers, recruitment of more microbiology labs to the MUTATE project and small grants research.

Combined Research 2020 Including Mutate Trial & Non-Antibiotic Alternatives fund represents monies donated to the above 2020 combination and includes expenditure on Non-Antibiotic alternatives.

TNL Scotland fund represents a National Lottery Award, monies donated are to be used to give Scottish Support Network for People Affected by antibiotic resistant infections in Aberdeen.

TNL England fund represents Coronavirus Community Support Fund grant from the National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in England.

The transfers represent the money spent in ANTRUK Enterprises Ltd on these projects.

Notes to the consolidated accounts for the year ended 31 December 2020

RESTRICTED FUNDS 2019

	2019				
	At 1.1.19 (£)	Income (£)	Expenditure (£)	Transfer (£)	At 31.12.19 (£)
Antibiotic Resistance Breakers	57,379	6,000	-	(500)	62,879
Patient Support	26,358	4,587	-	(22,825)	8,120
Combined Research Programmes	92,995	29,801	-	(64,040)	58,756
Test Discs	-	65,045	-	(7,859)	57,186
Combined Research Including Test Discs	-	73,514	-	(6,325)	67,189
	<u>176,732</u>	<u>178,947</u>	<u>-</u>	<u>(101,549)</u>	<u>254,130</u>

9. UNRESTRICTED FUNDS 2020

9. UNRESTRICTED FUNDS 2020		2020				
	At 1.1.20 (£)	Income (£)	Expenditure (£)	Transfer (£)	Tax (£)	At 31.12.20 (£)
General unrestricted funds	126,558	275,281	(239,349)	(19,665)	-	142,825
Non-charitable trading funds	4,985	15	(114,318)	110,780	4,244	5,706
	131,543	275,296	(353,667)	91,115	4,244	148,531

UNRESTRICTED FUNDS 2019

UNRESTRICTED FUNDS 2019	2019					
	At 1.1.19 (£)	Income (£)	Expenditure (£)	Transfer (£)	Tax (£)	At 31.12.19 (£)
General unrestricted funds	166,220	183,408	(211,720)	(11,350)	-	126,558
Non-charitable trading funds	839	-	(112,630)	112,899	3,877	4,985
	167,059	183,408	(324,350)	101,549	3,877	131,543

The transfers in both years represents the funds (both restricted for the projects and unrestricted for general expenses) transferred into ANTRUK Enterprises Limited.

Notes to the consolidated accounts for the year ended 31 December 2020

10. ANALYSIS OF NET ASSETS BETWEEN FUNDS

Fund balances at 31 December 2020 are represented by:	2020		
	Unrestricted funds (£)	Restricted funds (£)	Total (£)
GROUP			
Current assets	167,969	333,367	501,336
Creditors: amounts falling due in less than one year	(19,438)	-	(19,438)
Total net assets	148,531	333,367	481,898
CHARITY			
Investments	1	-	1
Current assets	159,258	333,367	492,625
Creditors: amounts falling due in less than one year	(16,433)	-	(16,433)
Total net assets	142,826	333,367	476,193

ANALYSIS OF NET ASSETS BETWEEN FUNDS

Fund balances at 31 December 2019 are represented by:	2019		
	Unrestricted funds (£)	Restricted funds (£)	Total (£)
GROUP			
Current assets	149,901	254,130	404,031
Creditors: amounts falling due in less than one year	(18,358)	-	(18,358)
Total net assets	131,543	254,130	385,673
CHARITY			
Investments	1	-	1
Current assets	141,529	254,129	395,658
Creditors: amounts falling due in less than one year	(14,971)	-	(14,971)
Total net assets	126,559	254,129	380,688

11. TRUSTEES' REMUNERATION & EXPENSES

No remuneration was paid or payable directly or indirectly out of the funds of the charity for the period to any trustee or to any person or persons known to be connected with any of them for acting as a trustee.

No trustees were reimbursed expenses (2019: 3 trustees amounting to £412).

12. RELATED PARTY TRANSACTIONS

Garner Consulting Services received £31,261 (2019: £30,229) for consultancy services. Also received was £31,261 (2019: £30,229) for research project management costs from ANTRUK Enterprises Ltd. As ANTRUK Enterprises Ltd is VAT registered the net cost was £26,051. The total cost to the group was £ 57,312 (2019: £55,419). Professor C Garner (Chief Executive of Antibiotic Research UK) and his wife are the partners in Garner Consulting Services. Of this amount £5,210 was owed to Garner Consulting Services at the year end (2019: £5,210).

Garbutt and Elliott LLP of which J A Farmer is a partner received £6,200 for accounting services (£5,200 through the charity and £1,000 through Enterprises) (2019: £4,340).

Ashurst LLP, of which N Stalbow is a partner, have provided pro bono services to the value of £26,412 (2019: £58,454).

The aggregated donations made by the trustees were £2,000 (2019: £500).

13. GRANT COMMITMENTS

Small grants committed at 31 December 2020 were £85,028 (2019: £85,242).

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

Text **FIGHT 10** to **70085**
to make a one-time £10 donation

Text **ANTI 10** to **70085**
to make an ongoing donation of £10 per month

Please obtain the bill payer's permission. Age 16+. UK mobile networks only. One off donations charged at £10 + std rate. Monthly subscription donations charged at £10 + std rate each month. Antibiotic Research UK (ANTRUK) is a registered charity in England & Wales (charity no.1157884).



**Antibiotic
RESEARCH UK**

**FIGHTING ANTIBIOTIC RESISTANCE
TODAY AND TOMORROW**

www.antibioticresearch.org.uk